var title_f20_46_21216="Patellar apprehension test";
var content_f20_46_21216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patellar apprehension test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with patellar dislocation and/or subluxation have pain in the medial patellar retinacular area and are apprehensive when the examiner tries to push the patella laterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21216=[""].join("\n");
var outline_f20_46_21216=null;
var title_f20_46_21217="NSAID induced strictures";
var content_f20_46_21217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaphragm-like strictures of the small intestine caused by NSAIDs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bjarnason I, et al. Side effects of nonsteroidal antiinflammatory drugs (NSAIDs) on the small and large intestine in humans. Gastroenterology 1993; 104:1832. Copyright &copy; 1993 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21217=[""].join("\n");
var outline_f20_46_21217=null;
var title_f20_46_21218="2-thumb method PI";
var content_f20_46_21218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infant CPR: 2-thumb method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 524px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressing on the chest for CPR is called doing \"compressions.\" To do compressions on an infant using the 2-thumb method, hold the infant with your hands around his or her chest. Then place the tips of your thumbs (side-by-side) on the victim's breastbone, just below the nipples. With each compression, make sure the victim's chest drops down at least 1.5 inches (3.8 centimeters). Between compressions, lift all pressure off the victim's chest so that his or her chest goes back to where it was.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21218=[""].join("\n");
var outline_f20_46_21218=null;
var title_f20_46_21219="Diagnosis and treatment of murine typhus";
var content_f20_46_21219=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of murine typhus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21219/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21219/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21219/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21219/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21219/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21219/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/46/21219/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 6, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8973214\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Murine (endemic) typhus is an uncommon flea-borne infectious disease caused by Rickettsia typhi. The illness is less commonly diagnosed in the United States than in the developing world because of improvements in hygiene and rat control efforts. The true incidence of this infection is difficult to establish because of the difficulty in distinguishing murine typhus from other causes of rash and fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8972893\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other rickettsial diseases, a reliable diagnostic laboratory test in the early phase of illness is not available. Thus, the diagnosis is usually based upon the typical clinical findings developing in an appropriate epidemiologic setting. The exposure history may not be helpful, since most patients do not remember a fleabite or contact with rodents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8973233\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of murine typhus includes many of the classic viral exanthems, such as rubella and measles, as well as numerous other viral infections (eg, mononucleosis, Coxsackievirus, Echovirus, Dengue virus), drug reactions, and other rickettsial diseases, such as RMSF and epidemic typhus. R. felis infection may mimic the clinical features of murine typhus and the two illnesses may produce similar convalescent serologic responses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28808?source=see_link\">",
"     \"Other spotted fever group rickettsial infections\"",
"    </a>",
"    .) Also, in areas such as Thailand and Taiwan where murine and scrub typhus are both endemic, it may be difficult or impossible to distinguish the two illnesses in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is usually confirmed serologically after a course of empiric therapy with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    . Although rickettsial cultures of blood, skin biopsy with direct fluorescent antibody staining, and polymerase chain reaction have been used to diagnose murine typhus, the mainstay of diagnosis is the indirect fluorescent antibody test. This test is available through all state health department laboratories. A diagnosis of murine typhus can be established by a fourfold antibody titer rise between acute and convalescent serum samples.",
"   </p>",
"   <p>",
"    However, it is important to note that R. typhi cross-reacts with R. prowazekii, the agent of epidemic typhus, and to a variety of spotted fever group antigens, including R. felis and R. rickettsii. Western blot testing and cross-adsorption studies can often help determine the infecting rickettsia in such cases. However, these techniques require specialized laboratories and such testing is expensive and time consuming [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymerase chain reaction technology can be used to confirm the diagnosis of murine typhus. This technique has been used successfully on blood, plasma, and tissue samples but is not widely available in routine clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8972900\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous recovery generally occurs within two weeks in untreated patients. Fatalities due to murine typhus are rare. In one large series, for example, only 2 of 80 patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in other rickettsial diseases, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    are the only effective antibiotics and hasten the rate of recovery. The drug of choice is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    in nonpregnant adults and children. The dose of doxycycline for adults should be 100 mg orally twice a day. Children weighing less than 45 kg should receive 0.9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses. Children weighing more than 45 kg should receive the adult dose.",
"   </p>",
"   <p>",
"    Tetracyclines can cause dental staining when administered to children. However, the risk of dental staining with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is minimal if a short course is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, this risk must be weighed against the one in 25,000 to 40,000 risk of fatal aplastic anemia due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    Most pediatric experts recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for suspected murine typhus even though the manufacturer does not publish dose recommendations for children less than age eight [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/6\">",
"     6",
"    </a>",
"    ]. Children weighing more than 45 kg should receive the adult dose; smaller children should receive 0.9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight in two divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is generally quite rapid. In the above series of 137 patients, defervescence within two days occurred more frequently in patients treated with doxycycline than in controls (79 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar findings were reported in a study of 23 children with murine typhus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/8\">",
"     8",
"    </a>",
"    ]. Defervescence occurred in a mean of 35 hours (range 4 to 66 hours) after the institution of doxycycline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ; treatment was started after a mean of 11 days of illness.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    is the drug of choice in pregnant women. The dose is 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally or intravenously in four divided doses, up to a maximum daily dose of 2 g.",
"   </p>",
"   <p>",
"    Although quinolones have been shown to be active against R. typhi in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/9\">",
"     9",
"    </a>",
"    ] and although some authors have suggested these agents as alternatives for the treatment of murine typhus for individuals unable to take tetracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/5\">",
"     5",
"    </a>",
"    ], there is no solid proof that such agents are effective. In one study patients treated with quinolones remained febrile longer than those who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8972907\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy for murine typhus has not been established in controlled clinical trials. Despite reported success with a single 200 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/1\">",
"     1",
"    </a>",
"    ], relapse of infection has been described in patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21219/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, we recommend that doxycycline be continued for 48 hours after the patient becomes afebrile or for a minimum of five days. Continuation of treatment for four to five days after the patient has become afebrile is recommended for patients treated with chloramphenicol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8973225\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with other rickettsial diseases, a reliable diagnostic laboratory test in the early phase of illness is not available. Thus, the diagnosis is usually based upon the typical clinical findings developing in an appropriate epidemiologic setting. The exposure history may not be helpful, since most patients do not remember a fleabite or contact with rodents. (See",
"      <a class=\"local\" href=\"#H8972893\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually confirmed after empiric therapy has been completed with an indirect fluorescent antibody test, which is available through all state health department laboratories. A diagnosis of murine typhus can be established by a fourfold antibody titer rise between acute and convalescent serum samples. (See",
"      <a class=\"local\" href=\"#H8972893\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of murine typhus includes many of the classic viral exanthems, such as rubella and measles, as well as numerous other viral infections (eg, mononucleosis, Coxsackievirus, Echovirus, Dengue virus), drug reactions, and other rickettsial diseases. (See",
"      <a class=\"local\" href=\"#H8973233\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in other rickettsial diseases, a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      are the only effective antibiotics and hasten the rate of recovery. The drug of choice is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      in nonpregnant adults and children. (See",
"      <a class=\"local\" href=\"#H8972900\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnant women with suspected murine typhus, the drug of choice is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8972900\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of therapy for murine typhus has not been established. (See",
"      <a class=\"local\" href=\"#H8972900\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/1\">",
"      Silpapojakul K, Chayakul P, Krisanapan S, Silpapojakul K. Murine typhus in Thailand: clinical features, diagnosis and treatment. Q J Med 1993; 86:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/2\">",
"      Suputtamonghol, Y, Suttinont, C, Niwatayakul, K, et al. Epidemiology and clinical aspects of rickettsiosis in Thailand. Ann NY Acad Sci 2009; 1166:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/3\">",
"      Purcell K, Fergie J, Richman K, Rocha L. Murine typhus in children, South Texas. Emerg Infect Dis 2007; 13:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/4\">",
"      Mouffok N, Parola P, Raoult D. Murine typhus, Algeria. Emerg Infect Dis 2008; 14:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/5\">",
"      Civen R, Ngo V. Murine typhus: an unrecognized suburban vectorborne disease. Clin Infect Dis 2008; 46:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/6\">",
"      Abramson JS, Givner LB. Should tetracycline be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than 9 years of age? Pediatrics 1990; 86:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/7\">",
"      Walker DH. Rocky Mountain spotted fever: a seasonal alert. Clin Infect Dis 1995; 20:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/8\">",
"      Fergie JE, Purcell K, Wanat D. Murine typhus in South Texas children. Pediatr Infect Dis J 2000; 19:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/9\">",
"      Strand O, Str&ouml;mberg A. Ciprofloxacin treatment of murine typhus. Scand J Infect Dis 1990; 22:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/10\">",
"      Gikas A, Doukakis S, Pediaditis J, et al. Comparison of the effectiveness of five different antibiotic regimens on infection with Rickettsia typhi: therapeutic data from 87 cases. Am J Trop Med Hyg 2004; 70:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21219/abstract/11\">",
"      Shaked Y, Samra Y, Maier MK, Rubinstein E. Relapse of rickettsial Mediterranean spotted fever and murine typhus after treatment with chloramphenicol. J Infect 1989; 18:35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16206 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-EA4EE1DDAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21219=[""].join("\n");
var outline_f20_46_21219=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8973225\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8973214\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8972893\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8973233\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8972900\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8972907\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8973225\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28808?source=related_link\">",
"      Other spotted fever group rickettsial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_46_21220="Neomycin, polymyxin B, and dexamethasone: Patient drug information";
var content_f20_46_21220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Neomycin, polymyxin B, and dexamethasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/31/34291?source=see_link\">",
"     see \"Neomycin, polymyxin B, and dexamethasone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/0/35842?source=see_link\">",
"     see \"Neomycin, polymyxin B, and dexamethasone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dioptrol&reg;;",
"     </li>",
"     <li>",
"      Maxitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702588",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to neomycin, polymyxin B, dexamethasone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705252",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a very bad eye infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10901 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21220=[""].join("\n");
var outline_f20_46_21220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158153\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158154\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013963\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013962\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013967\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013968\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013970\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013965\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013966\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013971\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013972\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/31/34291?source=related_link\">",
"      Neomycin, polymyxin B, and dexamethasone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/0/35842?source=related_link\">",
"      Neomycin, polymyxin B, and dexamethasone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_46_21221="Omega-3-acid ethyl esters (fish oil): Drug information";
var content_f20_46_21221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Omega-3-acid ethyl esters (fish oil): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/62/5093?source=see_link\">",
"    see \"Omega-3-acid ethyl esters (fish oil): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lovaza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Omega-3 Fatty Acids",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertriglyceridemia:",
"     </b>",
"     Oral: 4 g/day as a single daily dose or in 2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of IgA nephropathy (unlabeled use):",
"     </b>",
"     Oral: 4 g/day (Donadio, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F171386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid gel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lovaza&reg;: 1 g [contains DHA ~375 mg/capsule, EPA ~465 mg/capsule, soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F171371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Administer whole, do not break, crush, dissolve, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lovaza&reg;: Adjunct to diet therapy in the treatment of hypertriglyceridemia (&ge;500 mg/dL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The Endocrine Society recommends that omega-3 fatty acids such as Lovaza&reg; may be considered for triglyceride levels &gt;1000 mg/dL and may be used alone or in combination with HMG-CoA reductase inhibitors (Berglund, 2012). A number of OTC formulations containing omega-3 fatty acids are marketed as nutritional supplements; these do not have FDA-approved indications and may not contain the same amounts of the active ingredient.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F171396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lovaza&reg;: Treatment of IgA nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F1959598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lovaza&reg; may be confused with LORazepam",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Omacor [multiple international markets] may be confused with Amicar brand name for aminocaproic acid [U.S.]",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) reported a case of a foam plastic cup dissolving after contact with the liquid contents from a Lovaza&reg; capsule. ISMP is requesting the manufacturer to add warnings to its labeling and that healthcare providers add Lovaza&reg; to their list of medications to not crush.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Eructation (4%), taste perversion (4%), dyspepsia (3%), constipation, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic reaction, arrhythmia, asthma, bleeding diathesis, bleeding time prolonged, body odor, cardiac arrest, epistaxis, fecal incontinence, fever, gastritis, gastroenteritis, GI disorder, hyperlipemia, hypertension, melena, sudden death, vasodilatation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, anaphylactic reaction) to omega-3-acid ethyl esters or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fish allergy: Use with caution in patients with known allergy or sensitivity to fish and/or shellfish.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: ALT may increase without concurrent AST increase; periodically monitor hepatic transaminases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: May increase LDL levels; periodically monitor LDL levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolongation of bleeding time: Prolongation of bleeding time has been observed in some clinical studies; use with caution in patients with coagulopathy or in those receiving therapeutic anticoagulation. Monitor for changes in INR following initiation and dosage changes of omega-3-acid ethyl esters in patients receiving warfarin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrial fibrillation (AF): Omega-3-acid ethyl esters are not indicated for the treatment of AF or flutter. Recurrent AF or flutter may occur in patients with symptomatic paroxysmal or persistent AF treated with omega-3-acid ethyl esters; more frequent occurrences were observed with omega-3-acid ethyl esters in the first 2 to 3 months of therapy compared to placebo in clinical trials. However, the clinical significance of these results is uncertain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should be used as an adjunct to diet therapy and exercise and only in those with very high triglyceride levels (&ge;500 mg/dL). The Endocrine Society guidelines for the treatment of hypertriglyceridemia recommends that omega-3 fatty acids such as Lovaza&reg; may be considered for triglyceride levels &gt;1000 mg/dL and may be used alone or in combination with HMG-CoA reductase inhibitors (Berglund, 2012). Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inadequate response: If triglyceride levels do not adequately respond after 2 months of treatment with omega-3-acid ethyl esters, discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Omega-3 Fatty Acids may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F171379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Monitor ethanol use (alcohol use may increase triglycerides).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In some animal studies, embryocidal and maternal effects have been observed at high doses. There are no adequate or well-controlled studies in pregnant women. Use during pregnancy only if potential benefit outweighs possible risk.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F171376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Dietary modification is important in the control of severe hypertriglyceridemia. Maintain standard cholesterol-lowering diet during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Systane Omega-3 Healthy Tears Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $15.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Dialyvite Omega-3 Concentrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (60): $11.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Fish Oil Pearls Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (200): $14.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (180): $15.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (90): $10.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lovaza Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (120): $236.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (MiniCaps Omega-3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     350 mg (500): $100.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Omega-3 2100 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1050 mg (60): $16.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (RA Fish Oil Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     870 mg (120): $13.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Sea-Omega 30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200 mg (100): $6.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Super Omega 3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $10.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Super Twin EPA/DHA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1250 mg (100): $25.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ultra Omega 3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     952 mg (30): $14.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vascazen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (60): $77.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F171366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triglycerides and other lipids (LDL-C) should be monitored at baseline and periodically. Hepatic transaminase levels, particularly ALT, should be monitored periodically.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agemo (PK);",
"     </li>",
"     <li>",
"      Epax (EC);",
"     </li>",
"     <li>",
"      Equiplen (PE);",
"     </li>",
"     <li>",
"      Omacor (AT, AU, BE, BG, CR, CZ, DE, DO, EE, FI, FR, GB, GR, GT, HN, IE, IL, KP, NI, NL, NO, PA, PL, PT, RU, SV, TH);",
"     </li>",
"     <li>",
"      Triomar (IL);",
"     </li>",
"     <li>",
"      Ysomega (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism has not been completely defined. Possible mechanisms include inhibition of acyl CoA:1,2 diacylglycerol acyltransferase, increased hepatic beta-oxidation, a reduction in the hepatic synthesis of triglycerides, or an increase in plasma lipoprotein lipase activity.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, \"Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donadio JV and Grande JP, &ldquo;The Role of Fish Oil/Omega-3 Fatty Acids in the Treatment of IgA Nephropathy,&rdquo;",
"      <i>",
"       Semin Nephrol",
"      </i>",
"      , 2004, 24(3):225-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/15156528/pubmed\" id=\"15156528\" target=\"_blank\">",
"        15156528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donadio JV Jr, Larson TS, Bergstralh EJ, et al, &ldquo;A Randomized Trial of High-Dose Compared With Low-Dose Omega-3 Fatty Acids in Severe IgA Nephropathy,&rdquo;",
"      <i>",
"       J Am Soc Nephrol",
"      </i>",
"      , 2001, 12(4):791-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/11274240/pubmed\" id=\"11274240\" target=\"_blank\">",
"        11274240",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durrington PN, Bhatnagar D, Mackness MI, et al, &ldquo;An Omega-3 Polyunsaturated Fatty Acid Concentrate Administered for One Year Decreased Triglycerides in Simvastatin Treated Patients With Coronary Heart Disease and Persisting Hypertriglyceridaemia,&rdquo;",
"      <i>",
"       Heart",
"      </i>",
"      , 2001, 85(5):544-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/11303007/pubmed\" id=\"11303007\" target=\"_blank\">",
"        11303007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harris WS, Ginsberg HN, Arunakul N, et al, &ldquo;Safety and Efficacy of Omacor in Severe Hypertriglyceridemia,&rdquo;",
"      <i>",
"       J Cardiovasc Risk",
"      </i>",
"      , 1997, 4(5-6):385-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/9865671/pubmed\" id=\"9865671\" target=\"_blank\">",
"        9865671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kotwal S, Jun M, Sullivan D, et al, \"Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis,\"",
"      <i>",
"       Circ Cardiovasc Qual Outcomes",
"      </i>",
"      , 2012, 5(6):808-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/23110790/pubmed\" id=\"23110790\" target=\"_blank\">",
"        23110790",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kowey PR, Reiffel JA, Ellenbogen KA, et al, &ldquo;Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2010, 304(21):2363-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/21078810/pubmed\" id=\"21078810\" target=\"_blank\">",
"        21078810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Macchia A, Grancelli H, Varini S, et al, &ldquo;Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2013, 61(4):463&ndash;8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/23265344/pubmed\" id=\"23265344\" target=\"_blank\">",
"        23265344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mozaffarian D, Marchioli R, Macchia A, et al, \"Fish Oil and Postoperative Atrial Fibrillation: The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) Randomized Trial,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 308(19):2001-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/23128104/pubmed\" id=\"23128104\" target=\"_blank\">",
"        23128104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nodari S, Triggiani M, Campia U, et al, &ldquo;n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences after Electrical Cardioversion: A Prospective, Randomized Study,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(10):1100-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/21844082/pubmed\" id=\"21844082\" target=\"_blank\">",
"        21844082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizos EC, Ntzani EE, Bika E, et al, \"Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Meta-analysis,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 308(10):1024-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/22968891/pubmed\" id=\"22968891\" target=\"_blank\">",
"        22968891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stalenhoef AF, de Graaf J, Wittekoek ME, et al, &ldquo;The Effect of Concentrated n-3 Fatty Acids Versus Gemfibrozil on Plasma Lipoproteins, Low Density Lipoprotein Heterogeneity and Oxidizability in Patients With Hypertriglyceridemia,&rdquo;",
"      <i>",
"       Atherosclerosis",
"      </i>",
"      , 2000, 153(1):129-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21221/abstract-text/11058707/pubmed\" id=\"11058707\" target=\"_blank\">",
"        11058707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10255 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21221=[""].join("\n");
var outline_f20_46_21221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171381\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171400\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171384\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171385\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171386\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795613\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171368\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171371\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171370\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171396\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1959598\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171398\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171373\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171359\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299789\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171362\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171379\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171364\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171375\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171390\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171376\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422228\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171366\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539860\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171358\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/62/5093?source=related_link\">",
"      Omega-3-acid ethyl esters (fish oil): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_46_21222="Iron dextran: Drug information";
var content_f20_46_21222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iron dextran: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/15/33012?source=see_link\">",
"    see \"Iron dextran: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/20/9542?source=see_link\">",
"    see \"Iron dextran: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dexferrum&reg;;",
"     </li>",
"     <li>",
"      INFeD&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dexiron&trade;;",
"     </li>",
"     <li>",
"      Infufer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A 0.5 mL test dose should be given prior to starting iron dextran therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Iron-deficiency anemia:",
"     </b>",
"     I.M. (INFeD&reg;), I.V. (Dexferrum&reg;, INFeD&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose (mL) = 0.0442 (desired Hgb - observed Hgb) x LBW + (0.26 x LBW)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Desired hemoglobin: Usually 14.8 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     LBW = Lean body weight in kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Iron replacement therapy for blood loss:",
"     </b>",
"     (INFeD&reg;), I.V. (Dexferrum&reg;, INFeD&reg;): Replacement iron (mg) = blood loss (mL) x Hct",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Maximum daily dosage:",
"     </b>",
"     Manufacturer's labeling:",
"     <b>",
"      Note:",
"     </b>",
"     Replacement of larger estimated iron deficits may be achieved by serial administration of smaller incremental dosages. Daily dosages should be limited to 100 mg iron (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total dose infusion (unlabeled): The entire dose (estimated iron deficit) may be diluted and administered as a one-time I.V. infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cancer-/chemotherapy-associated anemia (NCCN guidelines v.2.2010) (unlabeled use):",
"     </b>",
"     I.V.: Test dose: 25 mg slow I.V. slow push, followed 1 hour later by 100 mg over 5 minutes; larger doses (unlabeled), up to total dose infusion (over several hours) may be administered. Low-molecular-weight iron dextran preferred.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F184556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/20/9542?source=see_link\">",
"      see \"Iron dextran: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     A 0.5 mL test dose (0.25 mL in infants) should be given prior to starting iron dextran therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Iron-deficiency anemia:",
"     </b>",
"     I.M. (INFeD&reg;), I.V. (Dexferrum&reg;, INFeD&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children  5-15 kg: Should not normally be given in the first 4 months of life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose (mL) = 0.0442 (desired Hgb - observed Hgb) x W + (0.26 x W)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Desired hemoglobin: Usually 12 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     W = Total body weight in kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;15 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Iron replacement therapy for blood loss:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Maximum daily dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;5 kg: 25 mg iron (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-10 kg: 50 mg iron (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;10 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dexferrum&reg;: Elemental iron 50 mg/mL (1 mL, 2 mL) [high-molecular-weight iron dextran]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     INFeD&reg;: Elemental iron 50 mg/mL (2 mL) [low-molecular-weight iron dextran]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F184528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Test dose: A test dose should be given on the first day of therapy; patient should be observed for 1 hour for hypersensitivity reaction, then the remaining dose (dose minus test dose) should be given. Resuscitation equipment and trained personnel should be available. An uneventful test dose does not ensure an anaphylactic-type reaction will not occur during administration of the therapeutic dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. (INFeD&reg;): Use Z-track technique (displacement of the skin laterally prior to injection); injection should be deep into the upper outer quadrant of buttock; alternate buttocks with subsequent injections. Administer test dose at same recommended site using the same technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Test dose should be given gradually over at least 30 seconds (INFeD&reg;) or 5 minutes (Dexferrum&reg;). Subsequent dose(s) may be administered by I.V. bolus undiluted at a rate not to exceed 50 mg/minute or diluted in 250-1000 mL NS and infused over 1-6 hours (initial 25 mL should be given slowly and patient should be observed for allergic reactions); avoid dilutions with dextrose (increased incidence of local pain and phlebitis)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F184567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of  iron deficiency in patients in whom oral administration is infeasible or ineffective",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9349476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cancer-/chemotherapy-associated anemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexferrum&reg; may be confused with Desferal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Iron dextran complex may be confused with ferumoxytol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Adverse event risk is reported to be higher with the high-molecular-weight iron dextran formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, chest pain, chest tightness, cyanosis, flushing, hyper-/hypotension, shock, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, disorientation, dizziness, fever, headache, malaise, seizure, unconsciousness, unresponsiveness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, taste alteration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (cellulitis, inflammation, pain, phlebitis, soreness, swelling), muscle atrophy/fibrosis (with I.M. injection), skin/tissue staining (at the site of I.M. injection), sterile abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis/arthritis exacerbation, back pain, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, respiratory arrest, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reactions (sudden respiratory difficulty, cardiovascular collapse), diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Angioedema, tumor formation (at former injection site)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron dextran or any component of the formulation; any anemia not associated with iron deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed reaction: Delayed (1-2 days) infusion reaction (including arthralgia, back pain, chills, dizziness, and fever) may occur with large doses (eg, total dose infusion) of I.V. iron dextran; usually subsides within 3-4 days. May also occur (less commonly) with I.M. administration; subsiding within 3-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Deaths associated with parenteral administration following anaphylactic-type reactions have been reported (use only where resuscitation equipment and personnel are available). A test dose should be administered to all patients prior to the first therapeutic dose. Anaphylactic and other hypersensitivity reactions have occurred even in patients who tolerated the test dose; observe for anaphylactic reactions during any iron dextran administration. A history of  drug allergy (including multiple drug allergies) and/or the concomitant use of an ACE inhibitor may increase the risk of anaphylactic-type reactions.",
"     </b>",
"     Adverse events (including life-threatening) associated with iron dextran usually occur more with the high-molecular-weight formulation (Dexferrum&reg;), compared to low-molecular-weight (INFeD&reg;) (Chertow, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergies/asthma: Use with caution in patients with a significant history of allergies or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cancer-associated anemia: In patients with cancer-related anemia (either due to cancer or chemotherapy-induced) requiring iron supplementation, the I.V. route is superior to oral therapy; I.M. administration is not recommended for parenteral iron supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease; iron dextran may exacerbate cardiovascular complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with extreme caution in patients with serious hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal disease/impairment: In patients with chronic kidney disease (CKD) requiring iron supplementation, the I.V. route is preferred for hemodialysis patients; either oral iron or I.V. iron may be used for nondialysis and peritoneal dialysis CKD patients. Avoid use during acute kidney infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may exacerbate joint pain and swelling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Anemia in the elderly is often caused by &ldquo;anemia of chronic disease&rdquo; or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. I.V. administration of iron dextran is often preferred over I.M. in the elderly secondary to a decreased muscle mass and the need for daily injections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not recommended in children &lt;4 months of age. Intramuscular iron dextran use in neonates may be associated with an increased incidence of gram-negative sepsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeablility: Iron dextran products differ in chemical characteristics. The high-molecular-weight formulation (Dexferrum&reg;) and the low-molecular-weight formulation (INFeD&reg;) are not clinically interchangeable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Use only in patients where the iron deficient state is not amenable to oral iron therapy. Discontinue oral iron prior to initiating parenteral iron therapy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinogenicity: Intramuscular injections of iron-carbohydrate complexes may have a risk of delayed injection site tumor development.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iron overload: Exogenous hemosiderosis may result from excess iron stores; patients with refractory anemias and/or hemoglobinopathies may be prone to iron overload with unwarranted iron supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6792945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. It is not known if iron dextran (as iron dextran) crosses the placenta. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6792947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trace amounts of iron dextran (as iron dextran) are found in human milk. Iron is normally found in breast milk. Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dexferrum Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (1 mL): $22.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Infed Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (2 mL): $37.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F184521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin, hematocrit, reticulocyte count, serum ferritin, serum iron, TIBC; monitor for anaphylaxis/hypersensitivity reaction (during test dose and therapeutic dose)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F184524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemoglobin: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 13.5-16.5 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 12.0-15.0 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum iron: 40-160 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total iron binding capacity: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cosmofer (AT, CL, DE, DK, FI, GB, GR, ID, IE, KP, NL, NO, PH, PT, SE, TH, VE);",
"     </li>",
"     <li>",
"      Desman (TW);",
"     </li>",
"     <li>",
"      Driken (MX);",
"     </li>",
"     <li>",
"      Fexibron (PE);",
"     </li>",
"     <li>",
"      Fexiron (AR, PE, PY);",
"     </li>",
"     <li>",
"      Imferon (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TR, YE);",
"     </li>",
"     <li>",
"      Supral (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The released iron, from the plasma, eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: I.V.: Serum ferritin peak: 7-9 days after dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 50% to 90% is promptly absorbed, balance is slowly absorbed over month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Uptake of iron by the reticuloendothelial system appears to be constant at about 10-20 mg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces via reticuloendothelial system",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Auerbach M, Ballard H, Trout JR, et al, &ldquo;Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Associated Anemia: A Multicenter, Open-Label, Randomized Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(7):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21222/abstract-text/15051778/pubmed\" id=\"15051778\" target=\"_blank\">",
"        15051778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Auerbach M, Witt D, and Toler W, &ldquo;Clinical Use of the Total Dose Intravenous Infusion of Iron Dextran,&rdquo;",
"      <i>",
"       J Lab Clin Med",
"      </i>",
"      , 1988, 111(5):566-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21222/abstract-text/3361236/pubmed\" id=\"3361236\" target=\"_blank\">",
"        3361236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benito RP and Guerrero TC, &ldquo;Response to a Single Intravenous Dose Versus Multiple Intramuscular Administration of Iron Dextran Complex: A Comparative Study,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1973, 15(7):373-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21222/abstract-text/4198298/pubmed\" id=\"4198298\" target=\"_blank\">",
"        4198298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chertow GM, Mason PD, Vaage-Nilsen O, et al, &ldquo;Update on Adverse Drug Events Associated With Parenteral Iron,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2006, 21(2):378-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21222/abstract-text/16286429/pubmed\" id=\"16286429\" target=\"_blank\">",
"        16286429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipschitz DA, &ldquo;The Anemia of Chronic Disease,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(11):1258-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21222/abstract-text/2123218/pubmed\" id=\"2123218\" target=\"_blank\">",
"        2123218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Cancer- and Chemotherapy-Induced Anemia Version 2.2010.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):529-30. Available at file://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm or  file://www.kidney.org/professionals/KDOQI",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizzo JD, Somerfield MR, Hagerty LK, et al, &ldquo;American Society of Hematology/American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(1):25-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21222/abstract-text/17954703/pubmed\" id=\"17954703\" target=\"_blank\">",
"        17954703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8574 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21222=[""].join("\n");
var outline_f20_46_21222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708946\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184543\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184544\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184562\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184546\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184556\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184547\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160032\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160033\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184523\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184507\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184528\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184567\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184527\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349476\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184569\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184560\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184531\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184511\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299544\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184516\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184519\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6792945\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184551\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6792947\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323229\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184521\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184524\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184533\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184510\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184530\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8574\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8574|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/15/33012?source=related_link\">",
"      Iron dextran: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/20/9542?source=related_link\">",
"      Iron dextran: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_46_21223="Telmisartan and amlodipine: Drug information";
var content_f20_46_21223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Telmisartan and amlodipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/21/19797?source=see_link\">",
"    see \"Telmisartan and amlodipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9524224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9508268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Twynsta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13265581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Twynsta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9524229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9524293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose is individualized; combination product may be substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within the same antihypertensive class). May also be used as initial therapy in patients who are likely to need &gt;1 antihypertensive to control blood pressure.",
"     <b>",
"      Note:",
"     </b>",
"     Use as initial therapy is not an approved indication in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Initial therapy (antihypertensive naive):",
"     </i>",
"     Telmisartan 40 mg/amlodipine 5 mg once daily; dose may be increased after 2 weeks of therapy. Patients requiring larger blood pressure reductions may be started on telmisartan 80 mg/amlodipine 5 mg once daily. Maximum recommended dose: Telmisartan 80 mg/day, amlodipine 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Add-on/replacement therapy:",
"     </i>",
"     Telmisartan 40-80 mg and amlodipine 5-10 mg once daily depending upon previous doses, current control, and goals of therapy; dose may be titrated after 2 weeks of therapy. Maximum recommended dose: Telmisartan 80 mg/day; amlodipine 10 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9524294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for initial therapy in patients &ge;75 years of age. For add-on/replacement therapy, initiate amlodipine therapy at 2.5 mg once daily and titrate slowly.",
"     <b>",
"      Note:",
"     </b>",
"     Use of individual agents may be necessary if the appropriate combination dose is not available.",
"     <b>",
"      Note:",
"     </b>",
"     Use as initial therapy is not an approved indication in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9524295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: No dosage adjustments are recommended; titrate slowly.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9524296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for initial therapy. For add-on/replacement therapy, initiate amlodipine at 2.5 mg once daily with low-dose telmisartan and titrate slowly;",
"     <b>",
"      Note:",
"     </b>",
"     Use of individual agents is necessary  as the appropriate combination dose is not available. Upon titration to therapeutic dose, may initiate combination dose if available. Canadian labeling contraindicates use in severe hepatic impairment or with biliary obstructive disorders.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9524302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     Twynsta&reg; 40/5: Telmisartan 40 mg and amlodipine 5 mg",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     Twynsta&reg; 40/10: Telmisartan 40 mg and amlodipine 10 mg",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     Twynsta&reg; 80/5: Telmisartan 80 mg and amlodipine 5 mg",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     Twynsta&reg; 80/10: Telmisartan 80 mg and amlodipine 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9524227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9524298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9524231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, including initial treatment in patients who will require multiple antihypertensives for adequate control",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9524242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Cardiovascular: Peripheral edema (dose related: 1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (6%), edema (&lt;2%), hypotension (&lt;2%), syncope (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (2%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9524237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amlodipine, telmisartan, or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to dihydropyridine derivatives; biliary obstructive disorders; severe hepatic impairment; cardiogenic shock; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9524238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with telmisartan use; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with telmisartan/amlodipine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; use caution during initiation of therapy, particularly in patients with heart failure, volume or salt depletion, severe aortic stenosis, or in post-MI patients or those undergoing surgery or dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect of amlodipine is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: Telmisartan may be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use caution when initiating in HF; may need to adjust dose, and/or concurrent diuretic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients who have biliary obstructive disorders or hepatic impairment; amlodipine and telmisartan clearance is decreased so initiation at the lowest dose is recommended; the appropriate dose for hepatic impairment is not available in combination dosage form,  therefore, initiation of treatment with this product is not recommended in patients with hepatic impairment. Canadian labeling contraindicates use in severe hepatic impairment or with biliary obstructive disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use telmisartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction; concurrent use with ramipril is not recommended. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Not recommended for initial therapy in patients &ge;75 years of age. The appropriate combination dose is not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorbitol: Formulation contains sorbitol; Canadian labeling contraindicates use in fructose-intolerant patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9524245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9613191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Telmisartan may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramipril: Telmisartan may increase the serum concentration of Ramipril. Concentrations of the active metabolite, ramiprilat, may also be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9524284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Rate and extent of telmisartan absorption (in combination with amlodipine) is decreased by 60% and 24%, respectively, when administered with a high-fat meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may decrease amlodipine levels. Avoid herbs with hypertensive properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice); may diminish the antihypertensive effect of telmisartan and amlodipine. Avoid herbs with hypotensive properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse); may enhance the hypotensive effect of telmisartan and amlodipine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9524232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9524233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9524235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9524236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9524297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid salt substitutes which may contain potassium. May be taken without regards to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Twynsta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-5 mg (30): $172.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-10 mg (30): $172.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-5 mg (30): $172.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-10 mg (30): $172.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9524300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic electrolyte panels (especially serum potassium); renal function (serum creatinine, BUN, urinalysis); hepatic function; heart rate, blood pressure, symptomatic hypotension, peripheral edema",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Micardis Amlo (AR, CN, CO);",
"     </li>",
"     <li>",
"      Twynsta (CZ, DE, EE, FR, HK, ID, IE, KP, MY, PH, PL, PT, SE, SG, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9524287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Telmisartan is a nonpeptide AT1 (angiotensin II type 1) receptor antagonist. Angiotensin II acts as a vasoconstrictor. In addition to causing direct vasoconstriction, angiotensin II also stimulates the release of aldosterone. Once aldosterone is released, sodium and water are reabsorbed. The end result is an elevation in blood pressure. Telmisartan binding to AT1 prevents angiotensin II from binding to the receptor thereby blocking the vasoconstriction and the aldosterone secreting effects of angiotensin II.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Amlodipine inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9524289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/46/21223/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9550 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21223=[""].join("\n");
var outline_f20_46_21223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524224\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508268\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265581\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524229\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524293\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524294\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524295\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524296\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524302\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524227\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524298\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524231\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524242\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524237\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524238\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524245\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9613191\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524284\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524232\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524233\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524235\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524236\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524297\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322732\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524300\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707704\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524287\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524289\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9550|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/21/19797?source=related_link\">",
"      Telmisartan and amlodipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_46_21224="Vagal maneuvers";
var content_f20_46_21224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vagal maneuvers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21224/contributors\">",
"     Daniel R Frisch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21224/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21224/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21224/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/46/21224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autonomic nervous system is composed of the sympathetic and parasympathetic divisions. This system innervates and regulates visceral functions including parenchymal cells and vascular smooth muscle cells.",
"   </p>",
"   <p>",
"    Preganglionic sympathetic neurons exit the central nervous system via the spinal cord between the first thoracic and second lumbar vertebrae, whereas preganglionic parasympathetic neurons exit the central nervous system via cranial nerves III, VII, IX, X and the second through fourth sacral nerves. In the thorax and abdomen, the vagus nerve dominates the parasympathetic nervous system.",
"   </p>",
"   <p>",
"    Various physical maneuvers can elicit autonomic responses. Many of these maneuvers can be performed at the bedside or in an office setting with minimal risk. These maneuvers can be both diagnostic (eg, in confirming carotid sinus hypersensitivity) and therapeutic (eg, terminating paroxysmal supraventricular tachycardia). Understanding the indications, techniques, and complications of various vagal maneuvers is necessary to safe and effective clinical application.",
"   </p>",
"   <p>",
"    Vagal maneuvers to evaluate and treat cardiac arrhythmias and conduction abnormalities are reviewed here. The general evaluation of parasympathetic nervous system function, of carotid sinus hypersensitivity, and of supraventricular tachycardia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3799?source=see_link\">",
"     \"Evaluation of parasympathetic nervous system function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIAC RESPONSES TO VAGAL STIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the heart, parasympathetic (vagal) stimulation causes local release of acetylcholine, with the following effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the sinus node, there is slowing of the rate of impulse formation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6614?source=see_link&amp;anchor=H6#H6\">",
"       \"Anatomy and electrophysiology of the sinoatrial node\", section on 'Autonomic influences'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the atrioventricular (AV) node, conduction velocity slows and the refractory period lengthens [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In atrial tissue, there is no change in conduction velocity, while the refractory period shortens [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The electrophysiologic properties of the His-Purkinje system do not change significantly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SELECTED TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of physical maneuvers can have intended or unintended influence on vagal tone. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Carotid sinus massage",
"     </li>",
"     <li>",
"      Valsalva maneuver",
"     </li>",
"     <li>",
"      Water immersion (diving reflex)",
"     </li>",
"     <li>",
"      Eyeball pressure (oculocardiac reflex)",
"     </li>",
"     <li>",
"      Breath-holding",
"     </li>",
"     <li>",
"      Rectal examination",
"     </li>",
"     <li>",
"      Coughing",
"     </li>",
"     <li>",
"      Deep respirations",
"     </li>",
"     <li>",
"      Gagging",
"     </li>",
"     <li>",
"      Intracardiac catheter placement",
"     </li>",
"     <li>",
"      Medical Anti-Shock Trousers (MAST garments)",
"     </li>",
"     <li>",
"      Nasogastric tube placement",
"     </li>",
"     <li>",
"      Squatting",
"     </li>",
"     <li>",
"      Trendelenburg position",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although only a small number of these maneuvers are used clinically (eg, carotid sinus massage and the Valsalva maneuver), it is useful to be aware of the potential autonomic impact of the others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Carotid sinus massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cerebrovascular and cardiovascular effects of carotid artery compression were documented at least as early as the 18th century [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/3\">",
"     3",
"    </a>",
"    ]. Early theories suggested that pressure on the carotid sinus directly stimulated the vagus nerve. However, later work demonstrated that distinct afferent nerve fibers are present in the carotid sinus and that these fibers join the glossopharyngeal nerve (cranial nerve IX) to directly stimulate medullary centers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carotid sinus massage (CSM) is commonly used in a variety of settings, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/1-13\">",
"     1-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The termination of SVT",
"     </li>",
"     <li>",
"      The evaluation of conduction abnormalities and AV block",
"     </li>",
"     <li>",
"      The diagnosis of carotid sinus hypersensitivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Previous investigations have suggested that right-sided carotid stimulation may preferentially impact the SA node and left-sided carotid stimulation may preferentially impact the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/14\">",
"     14",
"    </a>",
"    ], but this effect has never been clearly demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of CSM in diagnosis of syncope and carotid sinus hypersensitivity is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus massage should be avoided if there is a risk of stroke due to carotid artery disease. The American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     (AHA/ACC)",
"    </span>",
"    statement on syncope notes that CSM should not be performed in patients with recent transient ischemic attack or stroke, or ipsilateral significant carotid artery stenosis or carotid artery bruit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/15\">",
"     15",
"    </a>",
"    ]. The European Society of Cardiology (ESC) syncope guidelines recommend avoiding CSM in patients with history of transient ischemic attacks or stroke within the past three months, except if carotid Doppler studies exclude significant stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither syncope guideline specifically discusses pre-CSM screening for carotid disease beyond auscultation for carotid bruits. However, since a carotid bruit is not a sensitive indicator of carotid artery disease, it may be reasonable to perform carotid Doppler studies in high-risk patients such as those with vascular disease (coronary heart disease or peripheral artery disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34361?source=see_link\">",
"     \"Screening for asymptomatic carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional exclusion criteria have been used in some studies including recent myocardial infarction, history of ventricular arrhythmia, immobility, blindness, and cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus massage is performed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is placed in the supine position with the neck positioned (usually hyperextended) to maximize access to the carotid arterial impulse. The carotid sinus is usually located inferior to the angle of the mandible at the level of the thyroid cartilage near the arterial impulse (",
"      <a class=\"graphic graphic_figure graphicRef76761 \" href=\"UTD.htm?6/46/6884\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Simultaneous continuous electrocardiographic and blood pressure monitoring is required.",
"     </li>",
"     <li>",
"      Pressure is applied to one carotid sinus for 5 to 10 seconds. Although pulsatile pressure via vigorous circular motion may be more effective, steady pressure is recommended because it may be more reproducible [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a positive response a not obtained, the procedure is repeated on the other side after a one to two minute delay.",
"   </p>",
"   <p>",
"    In patients with normal sinus rhythm, the following responses may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/6\">",
"     6",
"    </a>",
"    ]: transient decrease in sinus rate, sinus pause, slowing of atrial conduction (with a change in P wave morphology), AV conduction delay or second degree heart block, atrial fibrillation, or a decrease in blood pressure. In some patients, these responses can lead to lightheadedness or syncope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that carotid sinus massage should be performed on one side before the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Valsalva maneuver",
"    </span>",
"    &nbsp;&mdash;&nbsp;A.M. Valsalva is credited with describing the maneuver that bears his name [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/17\">",
"     17",
"    </a>",
"    ]. In the original 1704 reporting, the use of the maneuver, forceful expiration against a closed mouth and nose, was beneficial in rapid expulsion of pus from the middle ear. Valsalva recommended this maneuver for such a purpose. Subsequent investigation of the Valsalva maneuver has focused on its cardiovascular and autonomic nervous properties. Clinical use has ranged from assessing left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] to treating conduction abnormalities (eg, paroxysmal supraventricular tachycardia) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various descriptions of the technique exist [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/5,7,18-20\">",
"     5,7,18-20",
"    </a>",
"    ]. While some descriptions have required patients to blow into a manometer to generate a certain amount of pressure (eg, 40 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/18\">",
"     18",
"    </a>",
"    ], this is not generally required [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The patient is placed in a supine position and instructed to exhale forcefully against a closed glottis after a normal inspiratory effort (ie, at tidal volume). Signs of adequacy include neck vein distension, increased tone in the abdominal wall muscles, and a flushed face. The patient should maintain the strain for 10 seconds and then release it and resume normal breathing.",
"   </p>",
"   <p>",
"    Blood pressure should be monitored during the maneuver. Depending upon the intention of the maneuver, ECG monitoring and heart rate may be observed as well. When monitoring blood pressure responses using a blood pressure cuff, the cuff should be inflated to approximately 15 mmHg above the patient's resting systolic blood pressure, and the investigator should auscultate the brachial artery throughout the maneuver and for 15 to 30 seconds afterwards.",
"   </p>",
"   <p>",
"    The expected response in normal subjects is divided into four phases (",
"    <a class=\"graphic graphic_figure graphicRef78776 \" href=\"UTD.htm?8/43/8895\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phase 1 is characterized by a &gt;15 mmHg rise in the patient's systolic blood pressure that occurs at the onset of the maneuver and typically lasts less than five seconds. Phase 1 occurs because of increased intrathoracic pressure.",
"     </li>",
"     <li>",
"      Phase 2 is typified by a return of the systolic blood pressure to baseline (below the 15 mmHg increase) during the remainder of the straining phase. Phase 2 occurs due to decreased venous return, subsequent decrease in stroke volume, and an increase in peripheral vascular resistance. Relative tachycardia may occur during this phase [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phase 3 occurs after release of the strain and is distinguished by an abrupt fall in systolic blood pressure below baseline. Phase 3 occurs due to an acute decrease in intrathoracic pressure. The decreased blood pressure is often not quantified (ie, the blood pressure cuff is usually maintained at a pressure 15 mmHg above the patient's resting systolic blood pressure).",
"     </li>",
"     <li>",
"      Phase 4 follows and is discerned by a secondary rise in systolic blood pressure &gt;15 mmHg above baseline. Phase 4 may occur because of a reflex sympathetic response to the decrease in systolic blood pressure encountered during phase 3. Relative bradycardia may occur during this phase [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three response patterns have been described in patients not taking beta-blocking agents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The normal pattern of systolic blood pressure has been named the \"sinusoidal\" response. The \"absent overshoot\" response is characterized by an absence of a Phase-4 rise in systolic blood pressure. This response is associated with a moderately decreased left ventricular ejection fraction. The \"square wave\" response is distinguished by the presence of Korotkoff sounds during the entire straining phase and an absence of a Phase-4 rise in systolic blood pressure. This response is associated with a severely decreased ejection fraction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 37 hemodynamically stable patients, a Valsalva maneuver was performed. These patients sought medical attention for dyspnea. They had chronic obstructive pulmonary disease and were not on beta&ndash;blocking agents, a bedside Valsalva maneuver was performed [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/20\">",
"       20",
"      </a>",
"      ]. The systolic blood pressure response to the Valsalva maneuver predicted left ventricular ejection fraction on radionuclide ventriculography. Those with a normal, sinusoidal response had a mean ejection fraction of 0.64 &plusmn; 0.13, those with an absent overshoot response had a mean ejection fraction of 0.42 &plusmn; 0.20, and those with a square root response had a mean ejection fraction of 0.19 &plusmn; 0.05.",
"     </li>",
"     <li>",
"      Bedside Valsalva maneuver was evaluated in another study of 37 patients referred for cardiac catheterization to evaluate dyspnea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest pain. Investigators found similar results to the above study in the 16 patients not on beta&ndash;blocking drugs. In the 21 patients taking beta-blockers, they found no correlation between a bedside Valsalva response and the left ventricular ejection fraction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diving reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diving reflex was first described in chickens and ducks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/21\">",
"     21",
"    </a>",
"    ], and has also been observed as an oxygen-conserving maneuver in diving mammals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/22\">",
"     22",
"    </a>",
"    ]. In humans, the diving reflex has been studied as a tool to assess the autonomic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3799?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of parasympathetic nervous system function\", section on 'Apneic facial immersion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to other vagal maneuvers, the diving reflex can potentially affect and terminate an SVT. However, due to the complexities involved, it is rarely used clinically.",
"   </p>",
"   <p>",
"    Various descriptions of the technique exist [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In one approach, the patient is seated in front of a basin of water with continuous electrocardiographic monitoring. The patient should be able to lean forward comfortably to submerge his or her face. The water should be at a temperature of 10 to 20&ordm;C and deep enough to allow complete facial immersion without the bowl touching the patient's neck. To minimize anxiety, the patient may practice holding his or her breath for 20 to 30 second intervals before immersion.",
"   </p>",
"   <p>",
"    To perform the maneuver, the patient takes a moderate breath, holds it, and then submerges his or her face in water for 20 to 30 seconds. A bradycardic response usually occurs within 10 to 30 seconds of breath holding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/22\">",
"     22",
"    </a>",
"    ]. If the inspiration is too deep, increased intrathoracic pressure may attenuate the bradycardic response. A complete response is more likely if a larger surface area is immersed, and contact of the area innervated by the ophthalmic division of the trigeminal nerve seems to be particularly sensitive. In addition, water temperatures below 10&ordm;C may prove too noxious a stimulus and cause anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The expected response in normal subjects results from a combination of facial immersion and breath holding. The expected effect is parasympathetic-mediated bradycardia and sympathetic-mediated peripheral vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/22\">",
"     22",
"    </a>",
"    ]. Just prior to facial immersion, anticipatory breath holding may result in transient tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/23\">",
"     23",
"    </a>",
"    ]. Ventricular ectopic beats may be observed, but ventricular arrhythmias have not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oculocardiac reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oculocardiac reflex involves a decrease in heart rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood pressure in response to eyeball pressure. The reflex is thought to originate from the ophthalmic portion of the trigeminal nerve. Afferent stimuli move through the reticular formation and nuclei of the vagus nerve output and proceed via an efferent link through the vagus nerve to cardiovascular structures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This oculocardiac reflex is most often recognized in the context of ophthalmic surgery. Pressure or traction on the orbital contents, globe, or extra-ocular muscles can produce unwanted and sometimes dangerous consequences, including lethal arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a clinical tool, the oculocardiac reflex is poorly defined and rarely used. It has been used to terminate SVTs and in the diagnostic evaluation of syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, due to limited utility, associated risks, and the availability of alternative maneuvers, we recommend that this test not be used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagal maneuvers can help manage various arrhythmias and conduction abnormalities (",
"    <a class=\"graphic graphic_table graphicRef67134 \" href=\"UTD.htm?17/45/18139\">",
"     table 1",
"    </a>",
"    ). The two maneuvers that are used most commonly in clinical practice are CSM and the Valsalva maneuver. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Carotid sinus massage'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Valsalva maneuver'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although vagal maneuvers have been described in a wide array of cardiovascular rhythm and hemodynamic scenarios, the most relevant use of vagal maneuvers include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supraventricular tachycardias &mdash; Vagal maneuvers can both diagnose and potentially treat supraventricular arrhythmias",
"     </li>",
"     <li>",
"      2:1 atrioventricular block &mdash; to help localize the site of the block",
"     </li>",
"     <li>",
"      Syncope &mdash; to help diagnose carotid sinus hypersensitivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term supraventricular tachycardia (SVT) refers to a variety of tachyarrhythmias that originate in atrial or AV nodal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/27\">",
"     27",
"    </a>",
"    ]. Reentry is the mechanism underlying the majority of regular, narrow complex SVTs, including atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT), both of which include the AV node in the reentrant circuit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maneuvers that increase vagal tone produce a progressive slowing of AV conduction and prolongation of AV nodal refractory periods, resulting in the alteration or termination many SVTs. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Cardiac responses to vagal stimulation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with an SVT of unclear etiology, maneuvers that increase vagal tone can lead to one of the following responses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slowing of AV nodal conduction to \"unmask\" atrial electrical activity (ie, reveal P waves or flutter waves in patients with atrial tachycardia or atrial flutter) (",
"      <a class=\"graphic graphic_waveform graphicRef76876 \" href=\"UTD.htm?33/18/34086\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With some narrow QRS complex tachycardias that require AV nodal conduction (eg, AVNRT and AVRT), vagal activation can interrupt the reentry circuit and stop the tachycardia. Less commonly, CSM can slow",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stop some atrial tachycardias.",
"     </li>",
"     <li>",
"      In patients with sinus tachycardia, the sinus rate can slow temporarily. This response may facilitate visualization of sinus P waves by separating them from preceding T waves [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to terminate SVT by vagal maneuvers has been documented since at least 1913 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/14\">",
"     14",
"    </a>",
"    ]. Successful termination of SVT by vagal maneuvers has been noted in as many as 72 percent of cases, although likelihood of success diminishes as the duration of the arrhythmia increases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/4\">",
"     4",
"    </a>",
"    ]. In AVNRT, augmented vagal tone can affect the anterograde slow and retrograde fast pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vagal maneuvers can stop spontaneous SVTs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/2,5\">",
"     2,5",
"    </a>",
"    ], and those induced during electrophysiology (EP) study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 18 patients with AVNRT induced by programmed electrical stimulation, carotid sinus massage successfully terminated the arrhythmia in 13 of the 18 patients (72 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Carotid sinus massage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relative efficacy of different maneuvers was evaluated in a series of 35 patients with SVT inducible by programmed electrical stimulation. Four vagal maneuvers were studied for their ability to terminate the tachycardia: the Valsalva maneuver, right carotid sinus massage, left carotid massage, and the diving reflex [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/7\">",
"       7",
"      </a>",
"      ]. The supine Valsalva maneuver was successful in 19 patients (54 percent), right and left carotid sinus massages were successful in six (17 percent) and two patients (5 percent), respectively, and the diving reflex was successful in six patients (17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Selected techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In one series of consecutive patients with recurrent SVT, various vagal techniques, including carotid sinus massage and the Valsalva maneuver, successfully terminated the SVT In 36 of 68 patients (53 percent) (",
"      <a class=\"graphic graphic_figure graphicRef55581 \" href=\"UTD.htm?1/59/1982\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/5\">",
"       5",
"      </a>",
"      ]. A gradual slowing of the tachycardia occurred before it stopped in most cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The direct role of increased vagal tone in stopping SVTs is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Successful arrhythmia termination with vagal maneuvers is associated with a greater degree of bradycardic response to vagal maneuvers while in sinus rhythm [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arrhythmia termination is often preceded by gradual slowing of the tachycardia, suggesting progressive prolongation of AV conduction during the maneuver [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/2,4,5\">",
"       2,4,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atrioventricular block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagal maneuvers, in particular CSM, can be helpful in determining the location of the conduction abnormality in a patient with 2:1 AV block (eg, within the AV node or in the His-Purkinje system) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/6\">",
"     6",
"    </a>",
"    ]. Increased vagal tone slows conduction through the AV node, but has little effect on conduction properties of the His-Purkinje system. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Cardiac responses to vagal stimulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because of the varying effects of vagal tone on sinus node, AV node, and His-Purkinje system properties, vagal maneuvers can identify the site of a conduction abnormality in patients with second degree AV block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased conduction defect with increased vagal tone (ie, higher-grade block) implies that the AV node is the site of the abnormality because the increased vagal tone prolongs AV node refractoriness and slows AV nodal conduction.",
"     </li>",
"     <li>",
"      Improvement in AV conduction (eg, restoration of 1:1 conduction) with vagal activation suggests that the conduction abnormality is below the level of the AV node. In such cases, a slower atrial rate provides greater recovery for the His-Purkinje system, thereby improving conduction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/6\">",
"       6",
"      </a>",
"      ]. An acceleration of the ventricular rate with carotid sinus massage in a patient with seemingly 1:1 AV conduction may indicate the presence of an underlying 2:1 AV block below the level of the AV node [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Carotid sinus hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus hypersensitivity is a common cause of syncope and is responsible for up to 23 to 46 percent of non-accidental falls in patients older than 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The disorder is diagnosed by performing carotid sinus massage in suspected patients. The diagnosis is confirmed in patients who respond to carotid sinus massage with sinus pauses of &gt;3 seconds (cardioinhibitory type), systolic blood pressure drops of &gt;50 mmHg (vasodepressor type), or both (mixed type) in the presence of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Evaluation of cardiac murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagal maneuvers can also be useful in the evaluation of cardiac murmurs. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagal maneuvers have been reported to be associated with termination of atrial fibrillation, atrial flutter and ventricular tachycardia (VT), and normalization of tachycardia-dependent left bundle branch block. It has been used to , predict left main coronary artery disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid sinus massage, and other vagal maneuvers can potentially stop atrial fibrillation and atrial flutter, but this is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/1,3,6,33,34\">",
"       1,3,6,33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vagal and sympathetictone may influence susceptibility to initiation and perpetuation of ventricular arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/9,35,36\">",
"       9,35,36",
"      </a>",
"      ]. Case reports and small series have documented termination of hemodynamically stable VT initiated during cardiac electrophysiological studies by vagal maneuvers [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/6,9,37\">",
"       6,9,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By slowing the heart rate with vagal activation, tachycardia-dependent intraventricular conduction delays and bundle branch blocks may be normalized [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/6,38\">",
"       6,38",
"      </a>",
"      ]. A potentially useful application of this observation may be in the setting of chest pain of uncertain etiology, as the electrocardiographic manifestations of acute myocardial injury may be masked in patients who present with concomitant left bundle branch block [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. However, vagal maneuvers should be used with caution in this setting due to the possibility of causing hemodynamic compromise and should be avoided in patients who are hemodynamically unstable.",
"     </li>",
"     <li>",
"      Vagal maneuvers may help predict severe and extensive coronary artery disease. In a series of 150 patients without a history of stroke, myocardial infarction, or previous coronary intervention, CSM was performed prior to angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/41\">",
"       41",
"      </a>",
"      ]. Cardioinhibitory, vasodepressor, or mixed carotid sinus hypersensitivity was noted in 6 to 14 percent of patients with no coronary disease or one or two-vessel disease. In contrast, these responses were noted in 19 of 33 (57.5 percent) and 11 of 15 (73.3 percent) patients with three vessel and left main stem disease, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiac complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In appropriately selected patients, vagal maneuvers are generally safe. However. interventions that alter cardiac conduction properties can result in adverse events, including the following (",
"    <a class=\"graphic graphic_table graphicRef79543 \" href=\"UTD.htm?14/50/15147\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sinus pauses",
"     </li>",
"     <li>",
"      AV block",
"     </li>",
"     <li>",
"      Less commonly, tachyarrhythmias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In rare cases, prolonged pauses, severe bradycardia, or malignant arrhythmias can have severe consequences.",
"   </p>",
"   <p>",
"    The potential complications of CSM and the oculocardiac reflex have been studied the most. The reported cardiac complications of CSM include ventricular tachycardia, ventricular fibrillation, and asystole. Although case reports describe these complications in patients with and without structural heart disease, many of the reports note that the affected patients were either taking digitalis or had serious underlying diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/3,6,11,12\">",
"     3,6,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neurologic complications of CSM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications of supine and upright CSM were infrequent (0.17 to 0.8 percent). Complications were usually transient in two retrospective studies (with 1719 and 4000 subjects) and one prospective study (with 1000 subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/13,16,42\">",
"     13,16,42",
"    </a>",
"    ]. Patients with prior strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/13,16,42\">",
"     13,16,42",
"    </a>",
"    ] or transient ischemic attack were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/16,42\">",
"     16,42",
"    </a>",
"    ]. Two studies employed additional exclusion criteria including carotid bruits, history of myocardial infarction, history of stroke, and history of ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/16,24\">",
"     16,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A neurologic event can occur up to two hours after CSM [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/16\">",
"     16",
"    </a>",
"    ]. Persistent neurologic deficits were reported in 0, 0.05 and 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/13,16,42\">",
"     13,16,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the cardiovascular complications common to all of these maneuvers, there are some maneuver-specific potential complications, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diving reflex (ice-water immersion) &ndash; Aspiration, drowning",
"     </li>",
"     <li>",
"      Oculocardiac reflex &ndash; Ocular injury",
"     </li>",
"     <li>",
"      Valsalva maneuver &ndash; Rupture of the round window of the ear",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CHOICE OF MANEUVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to identify which maneuver is the most useful given that certain vagal maneuvers may be more appropriate for particular situations (eg, CSM for the diagnosis of carotid sinus hypersensitivity) and most of the published experience is with CSM. However, there is a suggestion that the Valsalva maneuver may be the most effective in the termination of SVT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 35 patients with SVT inducible by programmed electrical stimulation mentioned above, of the four vagal maneuvers studied for their ability to terminate the tachycardia, investigators found that the supine Valsalva maneuver was successful in more instances (54 percent) than right carotid sinus massage (17 percent), left carotid sinus massage (5 percent), or the diving reflex (17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Supraventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a study of 68 consecutive patients with recurrent SVT, investigators compared various vagal techniques, including carotid sinus massage and the Valsalva maneuver, for the termination of the arrhythmia. The authors found that several patients who were unresponsive to multiple applications of carotid sinus massage terminated their arrhythmia with the Valsalva maneuver [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21224/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Supraventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=see_link\">",
"       \"Patient information: Vagal maneuvers and their responses (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagal maneuvers have diagnostic and therapeutic value in a variety of cardiovascular disorders. The principle clinical uses of these maneuvers are the diagnosis and termination of SVT, the detection of the level of 2:1 AV block, and the diagnosis of carotid sinus hypersensitivity. Because there are risks to performing vagal maneuvers, clinicians should be prepared for managing them should they occur.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/1\">",
"      Kirchhof CJ, Gorgels AP, Wellens HJ. Carotid sinus massage as a diagnostic and therapeutic tool for atrial flutter-fibrillation. Pacing Clin Electrophysiol 1998; 21:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/2\">",
"      Klein HO, Hoffman BF. Cessation of paroxysmal supraventricular tachycardias by parasympathomimetic interventions. Ann Intern Med 1974; 81:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/3\">",
"      Lown B, Levine SA. The carotid sinus: clinical value of its stimulation. Circulation 1961; 3:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/4\">",
"      Josephson ME, Seides SE, Batsford WB, et al. The effects of carotid sinus pressure in re-entrant paroxysmal supraventricular tachycardia. Am Heart J 1974; 88:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/5\">",
"      Waxman MB, Wald RW, Sharma AD, et al. Vagal techniques for termination of paroxysmal supraventricular tachycardia. Am J Cardiol 1980; 46:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/6\">",
"      Schweitzer P, Teichholz LE. Carotid sinus massage. Its diagnostic and therapeutic value in arrhythmias. Am J Med 1985; 78:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/7\">",
"      Mehta D, Wafa S, Ward DE, Camm AJ. Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet 1988; 1:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/8\">",
"      Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/9\">",
"      Hess DS, Hanlon T, Scheinman M, et al. Termination of ventricular tachycardia by carotid sinus massage. Circulation 1982; 65:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/10\">",
"      Cohn AE, Lewis T. The predominant influence of the left vagus nerve upon conduction between the auricles and ventricles in the dog. J Exper Med 1913; 18:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/11\">",
"      Deshpande SY, Merlino F, Cutts FB. Ventricular tachycardia and fibrillation due to carotid sinus stimulation. RI Med J 1968; 10:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/12\">",
"      Shookhoff C. Ventricular fibrillation with cardiac recovery, caused by carotid sinus pressure in a case of auricular fibrillation. Am Heart J 1931; 6:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/13\">",
"      Richardson DA, Bexton R, Shaw FE, et al. Complications of carotid sinus massage--a prospective series of older patients. Age Ageing 2000; 29:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/14\">",
"      Cohn AE, Fraser RF. Paroxysmal tachycardia and the effect of stimulation of the vagus nerves by pressure. Heart 1913; 5:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/15\">",
"      Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF Scientific Statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society. Circulation 2006; 113:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/16\">",
"      Davies AJ, Kenny RA. Frequency of neurologic complications following carotid sinus massage. Am J Cardiol 1998; 81:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/17\">",
"      DERBES VJ, KERR A Jr. Valsalva's maneuver and Weber's experiment. N Engl J Med 1955; 253:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/18\">",
"      IRVIN CW Jr. Valsalva maneuver as a diagnostic aid. J Am Med Assoc 1959; 170:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/19\">",
"      Zema MJ, Restivo B, Sos T, et al. Left ventricular dysfunction--bedside Valsalva manoeuvre. Br Heart J 1980; 44:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/20\">",
"      Zema MJ, Masters AP, Margouleff D. Dyspnea: the heart or the lungs? Differentiation at bedside by use of the simple Valsalva maneuver. Chest 1984; 85:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/21\">",
"      Reyners AK, Tio RA, Vlutters FG, et al. Re-evaluation of the cold face test in humans. Eur J Appl Physiol 2000; 82:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/22\">",
"      Gooden BA. The diving response in clinical medicine. Aviat Space Environ Med 1982; 53:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/23\">",
"      Duprez D, De Buyzere M, Trouerbach J, et al. Continuous monitoring of haemodynamic parameters in humans during the early phase of simulated diving with and without breathholding. Eur J Appl Physiol 2000; 81:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/24\">",
"      Van Brocklin MD, Hirons RR, Yolton RL. The oculocardiac reflex: a review. J Am Optom Assoc 1982; 53:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/25\">",
"      Brignole M, Menozzi C, Gianfranchi L, et al. Carotid sinus massage, eyeball compression, and head-up tilt test in patients with syncope of uncertain origin and in healthy control subjects. Am Heart J 1991; 122:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/26\">",
"      Allison CE, De Lange JJ, Koole FD, et al. A comparison of the incidence of the oculocardiac and oculorespiratory reflexes during sevoflurane or halothane anesthesia for strabismus surgery in children. Anesth Analg 2000; 90:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/27\">",
"      Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/28\">",
"      Josephson ME, Wellens HJ. Differential diagnosis of supraventricular tachycardia. Cardiol Clin 1990; 8:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/29\">",
"      Belz MK, Stambler BS, Wood MA, et al. Effects of enhanced parasympathetic tone on atrioventricular nodal conduction during atrioventricular nodal reentrant tachycardia. Am J Cardiol 1997; 80:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/30\">",
"      Richardson DA, Bexton RS, Shaw FE, Kenny RA. Prevalence of cardioinhibitory carotid sinus hypersensitivity in patients 50 years or over presenting to the accident and emergency department with \"unexplained\" or \"recurrent\" falls. Pacing Clin Electrophysiol 1997; 20:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/31\">",
"      Davies AJ, Steen N, Kenny RA. Carotid sinus hypersensitivity is common in older patients presenting to an accident and emergency department with unexplained falls. Age Ageing 2001; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/32\">",
"      O'Mahony D. Carotid sinus hypersensitivity in old age: clinical syndrome or physical sign? Age Ageing 2001; 30:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/33\">",
"      Ali N. Conversion of atrial flutter to sinus rhythm by carotid sinus pressure. J Natl Med Assoc 1982; 74:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/34\">",
"      Hellestrand KJ, Nathan AW, Camm AJ. Differential response to carotid sinus pressure during sinus rhythm and atrial fibrillation. Br Heart J 1982; 47:504.",
"     </a>",
"    </li>",
"    <li>",
"     Wagner, Galen S. Marriott's Practical Electrocardiography, 10th ed, Lippincott, Williams, and Wilkens, 2001.",
"    </li>",
"    <li>",
"     Schwartz PJ, Zipes DP. Role of the autonomic nervous system in ventricular tachyarrhythmias. UpToDate.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/37\">",
"      Wei JY, Greene HL, Weisfeldt ML. Cough-facilitated conversion of ventricular tachycardia. Am J Cardiol 1980; 45:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/38\">",
"      Harrington JF. Reversion of left-bundle-branch block to normal conduction by carotid-sinus pressure. N Engl J Med 1967; 277:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/39\">",
"      Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/40\">",
"      Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med 1996; 334:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/41\">",
"      Tsioufis CP, Kallikazaros IE, Toutouzas KP, et al. Exaggerated carotid sinus massage responses are related to severe coronary artery disease in patients being evaluated for chest pain. Clin Cardiol 2002; 25:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21224/abstract/42\">",
"      Puggioni E, Guiducci V, Brignole M, et al. Results and complications of the carotid sinus massage performed according to the \"method of symptoms\". Am J Cardiol 2002; 89:599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1034 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-CBD0E914AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21224=[""].join("\n");
var outline_f20_46_21224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIAC RESPONSES TO VAGAL STIMULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SELECTED TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Carotid sinus massage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Valsalva maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diving reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oculocardiac reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL USES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Evaluation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other uses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiac complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neurologic complications of CSM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CHOICE OF MANEUVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1034|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/46/6884\" title=\"figure 1\">",
"      Anatomy carotid sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/43/8895\" title=\"figure 2\">",
"      Valsalva blood pressure response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/59/1982\" title=\"figure 3\">",
"      Efficacy vagal maneuvers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/45/18139\" title=\"table 1\">",
"      Uses for vagal maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/50/15147\" title=\"table 2\">",
"      Complications of vagal maneuvers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1034|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?33/18/34086\" title=\"waveform 1\">",
"      Atrial flutter CS massage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6614?source=related_link\">",
"      Anatomy and electrophysiology of the sinoatrial node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3799?source=related_link\">",
"      Evaluation of parasympathetic nervous system function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=related_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34361?source=related_link\">",
"      Screening for asymptomatic carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_46_21225="Fibrillary glomerulonephritis EM";
var content_f20_46_21225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrillary glomerulonephritis EM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in fibrillary glomerulonephritis showing intramembranous and subendothelial fibrillary deposits (arrows). The glomerular basement membrane (GBM) is markedly disrupted by the infiltrating fibrils and a distinct lamina densa cannot be seen.",
"    <div class=\"footnotes\">",
"     En: endothelial cell; Ep: epithelial cell.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21225=[""].join("\n");
var outline_f20_46_21225=null;
var title_f20_46_21226="Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma";
var content_f20_46_21226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21226/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21226/contributors\">",
"     Jennifer A DeSimone, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21226/contributors\">",
"     Pritesh S Karia, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21226/contributors\">",
"     Chrysalyne D Schmults, MD, MSCE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21226/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/46/21226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/46/21226/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/46/21226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H90084715\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous squamous cell carcinoma (cutaneous SCC) is a relatively common malignancy derived from epidermal keratinocytes. Although most patients with cutaneous SCC present with localized disease that is cured with local treatment, tumor recurrence, metastasis, and death related to this disease occasionally occur. &ldquo;High-risk&rdquo; cutaneous SCCs are tumors that exhibit clinical or histologic features that have been associated with increased risk for aggressive tumor behavior. The best approach to the management of high-risk cutaneous SCC is not definitively known. Mohs micrographic surgery, surgical excision with complete tissue margin assessment, and radiation therapy are commonly used in the management of these lesions.",
"   </p>",
"   <p>",
"    The clinical and pathological features of high-risk cutaneous SCC and the management of patients with these tumors will be reviewed here. The risk factors and diagnosis of cutaneous SCC, the treatment of low-risk cutaneous SCC, and systemic therapy for advanced cutaneous SCC are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H858903\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous squamous cell carcinoma (cutaneous SCC) is the second most common human cancer with an estimated annual incidence of 186,157 to 419,843 cases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/1\">",
"     1",
"    </a>",
"    ]. Cutaneous SCC may occur in individuals of all races and ethnicities, but most frequently occurs in people with light skin who sunburn easily. Highly-curable, localized cutaneous SCC occurs most frequently; locoregional or distant metastases develop in less than 1 percent to 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. However, it has been estimated that deaths from cutaneous SCC are as common in the central and southern United States as deaths from many other common cancers including melanoma, leukemia, non-Hodgkin lymphoma, renal cancer, and bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the literature supports a correlation between certain clinical and pathological features of cutaneous SCC with increased risk for tumor recurrence and metastasis (",
"    <a class=\"graphic graphic_table graphicRef72651 \" href=\"UTD.htm?1/50/1837\">",
"     table 1",
"    </a>",
"    ), a lack of consensus over the definition of high-risk cutaneous SCC, a paucity of high-quality therapeutic studies, and the absence of a prognostic model that integrates multiple risk factors have made the prediction of patient outcomes and the formation of definitive management guidelines challenging. As an example, a survey-based study of 117 Mohs surgeons found a lack of consistency in the approach to the evaluation and management of high-risk SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084722\">",
"    <span class=\"h1\">",
"     HIGH-RISK FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of clinical and histopathologic factors have been proposed as indicators of increased risk for recurrence or metastasis of cutaneous squamous cell carcinoma (cutaneous SCC). However, as noted above, a consensus on which features define high-risk cutaneous SCC has not been established; major entities such as the National Comprehensive Cancer Network (NCCN) and the American Joint Committee on Cancer (AJCC) describe dissimilar &ldquo;high-risk&rdquo; criteria (",
"    <a class=\"graphic graphic_table graphicRef83683 graphicRef78140 \" href=\"UTD.htm?22/47/23294\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Examples of factors that have been associated with increased risk for metastasis or death on multivariate analysis in cohort studies include: clinical tumor diameter 2 cm or greater, depth of invasion &gt;6 mm or beyond the subcutaneous fat, poor differentiation, perineural invasion, location on the ear, and immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. These may be the most significant drivers of poor outcomes in SCC. However, all major characteristics that have been associated with aggressive tumor behavior are reviewed below (",
"    <a class=\"graphic graphic_table graphicRef72651 \" href=\"UTD.htm?1/50/1837\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084731\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings that have been used to identify high-risk cutaneous SCC include tumor location, tumor size, tumor status as primary or recurrent, and the presence of neurologic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084740\">",
"    <span class=\"h3\">",
"     Anatomic location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain tumor locations have been linked to increased risk for aggressive tumor behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Local recurrence of cutaneous SCC is estimated to occur in 2 to 22 percent of lip tumors and 3 to 20 percent of ear tumors, and metastasis develops in 5 to 19 percent and 9 to 12 percent of these lesions, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/11\">",
"     11",
"    </a>",
"    ]. The relatively thin nature of auricular skin and the low depth of invasion required for the tumor to invade the perichondrium (approximately 2 mm) may contribute to the increased risk for local recurrence observed with tumors on the ear. In addition, the proximity of the ear to the lymph nodes of the parotid gland and neck may be an important factor for metastasis. Tumors on the cheek also may portend an increased risk for metastasis compared to tumors in some other sites; a retrospective study of approximately 9000 cases of primary cutaneous SCC found that tumors on the auricular area, lip, and cheek were more likely to metastasize than tumors on the lower leg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084747\">",
"    <span class=\"h3\">",
"     Tumor diameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from multiple studies suggest that tumors 2 cm or larger in diameter are more likely to behave aggressively than smaller tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/4-6,12-16\">",
"     4-6,12-16",
"    </a>",
"    ]. A 1992 review found local recurrence rates for tumors &ge;2 cm and &lt;2 cm of 15 and 7 percent, respectively, and rates of metastasis of 30 versus 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/5\">",
"     5",
"    </a>",
"    ]. The findings of this review are corroborated by a retrospective study in which 25 of 200 cutaneous SCCs (12.5 percent) metastasized; skin tumors that metastasized were more likely than non-metastatic tumors to be larger than 2 cm (68 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AJCC staging system for cutaneous SCC designates a tumor size &gt;2 cm as important for disease staging (",
"    <a class=\"graphic graphic_table graphicRef78140 \" href=\"UTD.htm?5/0/5134\">",
"     table 2B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/4\">",
"     4",
"    </a>",
"    ]. Tumors that reach this threshold are automatically upstaged from T1 to T2. However, the possibility that smaller lesions may metastasize should always be considered, particularly for lesions on the head and neck. In a prospective study of 266 patients with cutaneous SCC that metastasized to parotid or cervical lymph nodes, 70 percent of lesions measured &le;2 cm, indicating that factors other than tumor size likely contribute to metastatic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/17\">",
"     17",
"    </a>",
"    ]. In concordance, lower size thresholds for identifying tumors on the head and neck as high-risk lesions have been proposed by some authors. The NCCN guidelines provide the following stratified approach for defining high-risk SCC (",
"    <a class=\"graphic graphic_table graphicRef83683 \" href=\"UTD.htm?21/43/22203\">",
"     table 2A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ge;2 cm on the trunk or extremities",
"     </li>",
"     <li>",
"      &ge;1 cm on the cheeks, forehead, scalp, or neck",
"     </li>",
"     <li>",
"      &ge;0.6 cm on the &ldquo;mask&rdquo; areas of the face (central face, eyelids, eyebrows, periorbital skin, nose, cutaneous or vermillion lip, chin, mandible, preauricular and postauricular skin, temple, and ear), genitalia, hands, and feet",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084754\">",
"    <span class=\"h3\">",
"     Recurrent tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with tumors that recur locally after initial treatment are associated with an increased risk for the development of distant metastatic disease. Between 30 and 50 percent of patients with metastatic cutaneous SCC have a history of local recurrence after surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/5,18,19\">",
"     5,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33739498\">",
"    <span class=\"h3\">",
"     Location in sites of chronic wounds, scars, or ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors that develop in sites of chronic wounds or scars have an increased likelihood for aggressive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/11,12,20\">",
"     11,12,20",
"    </a>",
"    ]. The risk for metastasis for these lesions ranges from 26 to 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/11\">",
"     11",
"    </a>",
"    ]. SCCs that arise in sites of prior radiation therapy may also be more likely to behave aggressively (",
"    <a class=\"graphic graphic_table graphicRef72651 \" href=\"UTD.htm?1/50/1837\">",
"     table 1",
"    </a>",
"    ). In a retrospective study of patients with cutaneous SCC that arose in sites of prior radiation therapy or burns, 14 of 20 patients (70 percent) treated with prior radiation and 24 of 46 patients (52 percent) with preceding burn injuries experienced local recurrence or metastasis after surgical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17872898\">",
"    <span class=\"h3\">",
"     Neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve involvement by cutaneous SCC may present with symptoms of pain, numbness, or weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/21\">",
"     21",
"    </a>",
"    ]. Deficits of cranial nerves V or VII are the most commonly detected neurologic symptoms with tumors on the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically evident invasion of named nerves may be associated with a lower likelihood for achieving local disease control than subclinical perineural invasion (PNI) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. In a retrospective study of 216 patients with PNI of head or neck squamous cell (n = 185), basal cell (n = 20), or basosquamous cell carcinoma (n = 11) whose treatment included radiation therapy, five-year outcomes data demonstrated that patients with clinically evident PNI were significantly less likely to attain local control than patients with subclinical PNI (80 versus 54 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the differences in the rates of locoregional control (70 versus 51 percent), distant metastasis (90 versus 94 percent), overall survival (55 versus 54 percent), and cause-specific survival (73 versus 64 percent) were not statistically significant. (See",
"    <a class=\"local\" href=\"#H90084775\">",
"     'Perineural invasion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084761\">",
"    <span class=\"h2\">",
"     Histologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic features such as the degree of tumor differentiation, histologic subtype, depth of tumor invasion, and the presence or absence of nerve involvement influence the prognosis of cutaneous SCC. Tumors with poorly differentiated histology, deep microinvasion, or perineural invasion are more likely to behave aggressively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4455948\">",
"    <span class=\"h3\">",
"     Histologic grade and subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-differentiated tumors are less likely to exhibit aggressive behavior than less differentiated tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/6,12,14\">",
"     6,12,14",
"    </a>",
"    ]. As an example, a retrospective study of 136 patients with invasive cutaneous SCC on the trunk or extremity treated at a tertiary care center between 1994 and 2004 found that poorly differentiated tumors were three times more likely than well-differentiated or moderately-differentiated tumors to result in metastasis or death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/12\">",
"     12",
"    </a>",
"    ]. Estimates of the risk for metastasis for poorly differentiated tumors have ranged from 33 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumors with desmoplastic (infiltrative) growth patterns may also exhibit aggressive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/2,24,25\">",
"     2,24,25",
"    </a>",
"    ]. Desmoplastic growth was an independent risk factor for tumor recurrence in a prospective study of 615 patients with cutaneous SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, a separate prospective study of 594 squamous cell carcinomas on the skin or lips found a 10-fold greater risk of local recurrence and a six-fold increased risk of metastasis among tumors with desmoplastic growth (n = 44) compared to tumors without this feature [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are limited on the relationship between other histologic subtypes and tumor aggressiveness. A 2011 review of published data found insufficient data to support the designation of acantholytic SCC as a tumor with increased risk for aggressive behavior or metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/26\">",
"     26",
"    </a>",
"    ], and the prognostic significance of cutaneous SCC with prominent mucin and a spindle cell component (myxoid spindle cell SCC) is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/27\">",
"     27",
"    </a>",
"    ]. At our institution, we have observed an association between cutaneous SCC with sarcomatoid differentiation or de-differentiation (loss of keratin staining) and aggressive tumor behavior and recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084768\">",
"    <span class=\"h3\">",
"     Tumor thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2010, tumor thickness was added to the AJCC staging system for cutaneous SCC due to the recognition of tumor thickness and depth of invasion as important prognostic factors in cutaneous SCC (",
"    <a class=\"graphic graphic_table graphicRef78140 \" href=\"UTD.htm?5/0/5134\">",
"     table 2B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/4\">",
"     4",
"    </a>",
"    ]. Utilizing measurement tools applied to cutaneous melanoma, a Breslow depth of greater than 2 mm and a Clark level of IV or higher were classified as high-risk features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H3#H3\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'Primary tumor (T)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective study of 673 SCCs of the skin or lip illustrated the importance of tumor thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/16\">",
"     16",
"    </a>",
"    ]. Whereas none of 325 tumors less than 2 mm thick metastasized during a follow-up period of up to 36 months after surgery, 9 of 60 tumors with depths greater than 6 mm (15 percent) metastasized. In addition, a subsequent prospective study of 615 patients with cutaneous SCC followed for a mean of 43 months detected no metastases among patients with tumors &le;2 mm deep [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, 12 of 318 tumors (4 percent) that were 2.1 to 6 mm deep and 14 of 90 tumors (16 percent) that were &gt;6 mm deep metastasized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084775\">",
"    <span class=\"h3\">",
"     Perineural invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perineural invasion (PNI) is associated with an increased incidence of tumor recurrence, metastasis, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/14,28-30\">",
"     14,28-30",
"    </a>",
"    ]. The local recurrence rate for tumors that exhibit this feature is estimated to be 16 to 47 percent and metastasis is estimated to occur in 10 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/11,30\">",
"     11,30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The caliber of the involved nerves in patients with PNI may provide additional prognostic information. Tumors with PNI of large nerves may portend a worse prognosis than tumors with smaller nerve involvement. The findings of a retrospective cohort study of 48 patients with cutaneous SCC and PNI (mean follow-up time = three years) support this concept; 8 of 25 patients (32 percent) with PNI involving nerves that were at least 0.1 mm in diameter died from cutaneous SCC versus 0 of 23 patients with PNI limited to smaller nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/14\">",
"     14",
"    </a>",
"    ]. Although a separate retrospective study that included 62 patients with cutaneous SCC and PNI who had the involved nerve diameter assessed failed to find a statistically significant impact of nerve diameter on prognosis, the study was limited to patients who were treated with both surgery and radiation, many of whom had positive surgical margins prior to radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/31\">",
"     31",
"    </a>",
"    ]. Thus, patients in this study may have had an increased likelihood for poor prognosis compared with the general population of patients with PNI.",
"   </p>",
"   <p>",
"    Tumors with PNI often have other high-risk features that may impact prognosis. This was illustrated in a retrospective study of 114 cases of cutaneous SCC with PNI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/30\">",
"     30",
"    </a>",
"    ]. Although the study found worse prognoses in patients with cutaneous SCC with PNI of large nerves (&ge;0.1 mm diameter) than in patients with PNI of smaller nerves (&lt;0.1 mm diameter) on univariate analysis, nerve caliber did not predict outcomes on multivariate analysis since many subjects had other prognostic risk factors, regardless of nerve caliber. This underscores the need for larger studies to clarify the risk associated with each risk factor since factors are often co-linear with multiple factors occurring together in a given patient or tumor. Patients who had small caliber nerve invasion but had no other risk factors did very well (0 percent risk of nodal metastasis and 0 percent risk of death from SCC) indicating that PNI invasion alone may not necessarily confer a poor prognosis if it is not extensive. Additional studies are necessary to clarify the impact of PNI on prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084805\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid conditions such as immunodeficiency, chronic lymphocytic leukemia (CLL), and recessive dystrophic epidermolysis bullosa may negatively influence the prognosis of cutaneous SCC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immunosuppression &ndash;",
"      </strong>",
"      Immunosuppression, resulting directly from disease or secondary to its treatment, is the strongest host risk factor for poor outcomes in patients with cutaneous SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/32\">",
"       32",
"      </a>",
"      ]. Immunosuppressed organ transplant recipients have a particularly high risk for the development of frequent and aggressive tumors. The incidence of cutaneous SCC is estimated to be 65 to 250 times greater in organ transplant recipients than in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Moreover, tumors in immunosuppressed patients may demonstrate more rapid growth, an increased likelihood for local recurrence, and a 5 to 10-fold increased risk for metastasis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/32,35,36\">",
"       32,35,36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The development of cutaneous SCC in iatrogenically immunosuppressed patients is a multifactorial phenomenon. The specific drug(s) administered, the medication dose, the duration of treatment, and host risk factors (eg, skin phenotype, age, and cumulative ultraviolet exposure) influence the risk of tumor development. Cutaneous SCC in immunosuppressed organ transplant recipients is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37832?source=see_link&amp;anchor=H7860393#H7860393\">",
"       \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\", section on 'Squamous cell and basal cell carcinoma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link&amp;anchor=H2294558#H2294558\">",
"       \"Management of skin cancer in solid organ transplant recipients\", section on 'Squamous cell carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic lymphocytic leukemia &ndash;",
"      </strong>",
"      Chronic lymphocytic leukemia (CLL) impairs host immune function and may be a risk factor for recurrent and metastatic cutaneous SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. In a retrospective study of 57 tumors in 28 patients with CLL and 114 tumors in patients without CLL that were treated with Mohs surgery, the rate of tumor recurrence was significantly greater among patients with CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/39\">",
"       39",
"      </a>",
"      ]. Tumors were seven times more likely to recur in the CLL population (adjusted risk ratio 7.0, 95% CI 2.1-22.8), and five years after surgical resection, the cumulative incidence of tumor recurrence was 19 versus 4 percent. Moreover, a statistically significant increase in the rates of metastasis and death from cutaneous SCC in patients with CLL was detected in a separate retrospective study with a mean follow-up period of four years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/38\">",
"       38",
"      </a>",
"      ]. In the study, 3 of 28 patients with CLL developed metastases and died versus 0 of 56 patients without this hematologic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link\">",
"       \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"       \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermolysis bullosa &ndash;",
"      </strong>",
"      Cutaneous SCC is a common occurrence in patients with recessive dystrophic epidermolysis bullosa and metastatic cutaneous SCC is the primary cause of death in these patients. Approximately 55 percent of patients die from metastatic disease by age 40 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H17#H17\">",
"       \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Epidermolysis bullosa'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link&amp;anchor=H61550613#H61550613\">",
"       \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\", section on 'Skin cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prognostic data are insufficient to estimate the risk for adverse outcomes from cutaneous SCC in other comorbidities in which the development of aggressive or metastatic cutaneous SCC has been reported. Examples include discoid lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], sclerodermatous disorders (systemic sclerosis, generalized morphea, and chronic graft-versus host disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], and hidradenitis suppurativa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4456126\">",
"    <span class=\"h2\">",
"     Other features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4456021\">",
"    <span class=\"h3\">",
"     Nuclear morphometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective case series of 40 patients evaluated the utility of nuclear morphometry (karyometry) for differentiating between aggressive and nonaggressive SCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/47\">",
"     47",
"    </a>",
"    ]. Investigators found that karyometric classification scores correlated with tumor behavior; the score accurately categorized tumor in 80 percent of patients. Further studies are necessary to determine the role of such testing in the management of cutaneous SCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4456036\">",
"    <span class=\"h3\">",
"     Epidermal growth factor receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although overexpression of the epidermal growth factor receptor (EGFR) has been associated with aggressive clinical behavior in head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/48-50\">",
"     48-50",
"    </a>",
"    ], the prognostic value of EGFR expression levels in lesions of cutaneous SCC is uncertain. Evidence in support of a relevant role of EGFR expression includes a retrospective study that found that primary cutaneous SCCs that subsequently metastasized were significantly more likely to overexpress EGFR than tumors that did not metastasize (11 of 14 versus 9 of 25 tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/51\">",
"     51",
"    </a>",
"    ], as well as documentation of improvement of advanced or unresectable cutaneous SCC after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , an EGFR inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/52,53\">",
"     52,53",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link&amp;anchor=H1587553565#H1587553565\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\", section on 'EGFR pathway'",
"    </a>",
"    ). However, a retrospective study of 56 patients with advanced cutaneous SCC on the head or neck found no association between EGFR overexpression and aggressive disease or patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084812\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regional lymph nodes are the most common initial site of metastasis in cutaneous squamous cell carcinoma (cutaneous SCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/4\">",
"     4",
"    </a>",
"    ]. A beneficial role of early detection of metastatic disease on patient outcomes is supported by the observation that patients with limited operable nodal involvement are more likely to be cured (five-year survival of 73 percent) than patients with extensive nodal disease (five-year survival of 26 to 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. However, definitive guidelines for staging patients with high-risk cutaneous SCC have not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084821\">",
"    <span class=\"h2\">",
"     Staging systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2010, the American Joint Committee on Cancer (AJCC) revised its staging system for cutaneous SCC based on expert review of the available evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/4\">",
"     4",
"    </a>",
"    ]. The system classifies cases by tumor burden (T), nodal involvement (N), and metastatic disease (M). The major changes compared to the previous staging system are the separation of cutaneous SCC from other nonmelanoma skin cancers and the incorporation of risk factors of anatomic location, tumor depth, histological differentiation, and perineural invasion into the T-classification. A table that demonstrates the AJCC staging criteria is provided (",
"    <a class=\"graphic graphic_table graphicRef78140 \" href=\"UTD.htm?5/0/5134\">",
"     table 2B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 2010 AJCC staging system is generally considered to be an improvement over the previous version for the staging of patients with cutaneous SCC. However, further alterations to the staging system have been proposed based upon studies that suggest that the new AJCC staging system may not optimally stratify the prognostic groups for cutaneous SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/9,55,56\">",
"     9,55,56",
"    </a>",
"    ]. In a retrospective study of 256 cutaneous SCC cases, only 2 percent of the cohort (four cases) met AJCC stage T3 or T4 criteria owing to the rarity of bone invasion that is required for these stages. Most poor outcomes were clustered in stage T2 (69 percent local recurrence, 83 percent nodal metastases, and 92 percent of deaths from cutaneous SCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/9\">",
"     9",
"    </a>",
"    ]. An alternative T stage system was therefore developed with the aim of prognostically stratifying AJCC stage T2. Likewise, a retrospective study of 603 patients found that stages N2a, N2c, and N3 of the AJCC staging system contained less than 10 percent of patients and that this division of stages lacked prognostic relevance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/55\">",
"     55",
"    </a>",
"    ]. An alternative nodal staging system developed for head and neck cancer (N1S3) was a simpler and effective method for stratifying patients in this study. Additional research on patient outcomes from cutaneous SCC will be useful for confirming which adjustments to the AJCC staging system are indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084828\">",
"    <span class=\"h2\">",
"     Tools for staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic imaging is the diagnostic modality of choice for assessment for bone invasion (needed for T3 or T4 staging) and determination of nodal and distant metastatic involvement in patients with high-risk cutaneous SCC. Computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound have been utilized for disease staging. In general, CT is most appropriate in the detection of bone invasion, cartilage invasion, and nodal necrosis, while MRI is best suited to evaluate for tumor extension into soft tissue and large nerves. Clinically detectable enlarged lymph nodes can be evaluated via fine needle aspiration or surgical excision. The evaluation for regional and distant metastases in patients with cutaneous SCC is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084835\">",
"    <span class=\"h2\">",
"     Sentinel lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sentinel lymph node (SLN) biopsy is a surgical procedure utilized to detect subclinical nodal metastases in melanoma and multiple other malignancies. High-quality studies evaluating the use of SLN biopsy in high-risk cutaneous SCC are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/11,57\">",
"     11,57",
"    </a>",
"    ]. The effect of this procedure on patient survival is unclear. However, as staging systems evolve and more precisely define those with a 10 percent or higher risk of nodal metastasis, this may be a group worthy of SLN biopsy consideration as in melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link&amp;anchor=H2824518#H2824518\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\", section on 'Sentinel lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084842\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early and aggressive surgical excision is the primary modality utilized for the management of patients with localized cutaneous squamous cell carcinoma (cutaneous SCC) that exhibits one or more high risk features. Treatment modalities that do not provide opportunities to assess the tissue margins such as cryosurgery, electrodesiccation and curettage, topical therapies, and photodynamic therapy are not recommended. Radiation therapy is sometimes used as adjunctive therapy in an attempt to reduce the risk for disease recurrence; the indications for doing so remain unclear. Radiation may also be employed as salvage or palliative therapy when complete surgical removal is not possible. Patients with locally advanced or metastatic disease that cannot be effectively managed with surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation are candidates for systemic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with locally advanced or metastatic disease often benefit from management by a multidisciplinary team (eg, a dermatologic surgeon, otolaryngologist, surgical oncologist, radiation oncologist,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical oncologist). Organ transplant recipients may also benefit from collaboration with transplant clinicians to assess for the need for modification of their immunosuppressive regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link&amp;anchor=H2294607#H2294607\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Modulation of immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084851\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is the primary treatment modality utilized for the management of high-risk cutaneous SCC. Options include Mohs micrographic surgery (MMS), surgical excision with complete circumferential peripheral and deep margin assessment (CCPDMA), and conventional surgical excision. MMS and excision with CCPDMA are preferred over conventional surgical excision since these procedures assess complete tumor removal via the examination of 100 percent of the tissue margin. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262413\">",
"    <span class=\"h3\">",
"     Mohs surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMS is performed under local anesthesia by a surgeon (usually a dermatologic surgeon) specifically trained in the technique. During the procedure, frozen sections encompassing 100 percent of the tissue margin are examined by the surgeon, allowing for confirmation of the removal of the tumor prior to wound closure. The MMS technique is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although randomized trials comparing MMS to conventional surgical excision have not been performed, MMS has the highest reported cure rates for primary cutaneous SCC.",
"   </p>",
"   <p>",
"    Examples of studies that support the efficacy of MMS for high-risk SCC include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study in which 215 patients with 260 high-risk tumors (defined as a site on the ear or lip, or temple in elderly men; size greater than 2 cm; rapid growth larger than 1 cm; perineural involvement; or occurring in the setting of immunosuppression) were treated with MMS, the recurrence rate after almost four years was only 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 1992 systematic review found that SCCs on the skin or lip were less likely to recur after treatment with MMS than other treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/5\">",
"       5",
"      </a>",
"      ]. Overall recurrence rates for MMS, surgical excision, and all non-Mohs treatment modalities (cryotherapy, electrodesiccation and curettage, surgical excision, and radiation therapy) were 3, 8, and 8 percent, respectively. The frequency of recurrence among tumors with high-risk features was also lower when compared with all non-MMS treatment modalities. The rates of recurrence were as follows: location on the lip (3 versus 11 percent), location on the ear (5 versus 19 percent), tumors &ge;2 cm in size (25 versus 42 percent), locally recurrent tumors (10 versus 23 percent), tumors with perineural invasion (PNI) (0 versus 47 percent), and poorly differentiated tumors (33 versus 54 percent).",
"     </li>",
"     <li>",
"      A case series that included 381 patients with primary (n = 229) or recurrent (n = 152) cutaneous SCC followed for five years after MMS found recurrence rates of 3 and 6 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/59\">",
"       59",
"      </a>",
"      ]. In this series, 96 percent of tumors were located on the head or neck (including 18 percent in the auricular region), 32 percent of tumors were greater than or equal to 2 cm in size, and 13 percent of tumors were poorly differentiated. A small minority of patients were also treated with radiation, including more than half of the patients with PNI. Two out of 25 patients with PNI had disease recurrence (8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to its tissue-sparing effects, Mohs surgery is also used for tumors without high-risk features that are located in cosmetically sensitive areas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Criteria for the appropriate use of Mohs surgery have been developed by a panel of clinicians from the American Academy of Dermatology, the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/61\">",
"     61",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262420\">",
"    <span class=\"h3\">",
"     Excision with complete margin assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision with complete circumferential peripheral and deep margin assessment (CCPDMA) is an alternative to Mohs surgery. The procedure involves the examination of the entire margin of the tissue specimen by a pathologist. Histopathologic examination may be performed intraoperatively with frozen sections or with permanent sections and delayed wound closure.",
"   </p>",
"   <p>",
"    Surgical excision with CCPDMA is typically performed for advanced tumors that are best approached under general anesthesia due to large tumor size or great depth. CCPDMA is also useful when the continuous layers of tissue removed during Mohs surgery are not ideal, such as when surgical preservation of important deep anatomic structures (eg, major vessels or nerves) is required. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262427\">",
"    <span class=\"h3\">",
"     Conventional surgical excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;In accordance with guidelines proposed by the NCCN, conventional surgical excision is appropriate only for tumors on the trunk or extremities that have a size greater than 2 cm as the",
"    <strong>",
"     only",
"    </strong>",
"    high-risk feature [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/8\">",
"     8",
"    </a>",
"    ]. Such tumors should be excised with a 1 cm margin and primary closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H480333\">",
"    <span class=\"h3\">",
"     Extensive cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete removal of the tumor can be challenging in patients with PNI involving large nerves or deep invasion into underlying tissues or bone. Aggressive surgical resections of named nerves",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the skull base to achieve clear margins have been beneficial in some patients with head or neck tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases characterized by deep or extensive local tumor involvement MMS may be used as a preliminary step prior to deeper dissection to establish the peripheral margin and clarify the locations where deeper dissection is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/64\">",
"     64",
"    </a>",
"    ]. This approach may minimize the time required for general anesthesia. Preoperative imaging to evaluate the extent of disease is also advised [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084858\">",
"    <span class=\"h2\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation is not routinely utilized as monotherapy for high-risk cutaneous SCC due to a relatively high rate of local recurrence (15 to 20 percent or greater) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] and the potential for long-term adverse effects (",
"    <a class=\"graphic graphic_table graphicRef82148 \" href=\"UTD.htm?12/54/13163\">",
"     table 3",
"    </a>",
"    ). The use of radiation therapy as primary therapy is typically reserved for patients over the age of 60 who are not candidates for surgical therapy due to significant comorbidities or other factors and for palliative cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329859#H12329859\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More commonly, radiation therapy is combined with surgery. Patients may receive radiation to the sites of high-risk tumors as an adjuvant therapeutic measure aimed at reducing the likelihood for local recurrence following a surgical excision with clear margins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/19\">",
"     19",
"    </a>",
"    ]. Alternatively, radiation therapy is given as a salvage therapy for patients with incompletely resected tumors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Adjuvant radiation therapy &ndash;",
"      </strong>",
"      Data on adjuvant radiation therapy (ART) for primary cutaneous SCC excised with clear surgical margins are limited and a survival benefit is uncertain. A 2009 systematic review that identified 91 patients treated with surgery and ART and 2358 patients treated with surgery alone found high cure rates among cases in which documentation specified the attainment of clear margins, but failed to find sufficient data to indicate which patients benefit from ART [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/68\">",
"       68",
"      </a>",
"      ]. Differences in local recurrence and disease specific death rates were not detected between the two groups. Moreover, among patients with PNI, statistically significant differences in patient outcomes were not detected.",
"      <br/>",
"      <br/>",
"      Thus, definitive recommendations on the indications for ART are lacking. Guidelines from the NCCN suggest the use of ART for tumors that exhibit extensive perineural or large-nerve involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/8\">",
"       8",
"      </a>",
"      ], and there is general agreement among clinicians that patients with PNI of large named nerves, lymph node involvement, massive local extension, or intracranial invasion are appropriate candidates for post-surgical ART [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. We also consider the use of ART in patients with multiple high-risk features, PNI of unnamed nerves &gt;0.1 mm in diameter, two or more nerves demonstrating PNI in the pathology specimen, or multiple tumor recurrences [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/14,64\">",
"       14,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Salvage radiation therapy &ndash;",
"      </strong>",
"      In general, patients who have clear surgical margins prior to ART have better outcomes than patients given radiation therapy following incomplete surgical clearance (salvage radiation therapy) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/62,67,68\">",
"       62,67,68",
"      </a>",
"      ]. Thus, complete surgical excision is the preferred initial therapy whenever feasible [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/62,68,70\">",
"       62,68,70",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, complete tumor resection is not always possible without introducing an unacceptable level of morbidity, such as some cases of widespread skull base invasion or advanced intracranial extension. In such cases, radiation therapy is administered in an attempt to destroy surgically inaccessible tumor remnants [",
"      <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/8\">",
"       8",
"      </a>",
"      ]. The efficacy of radiation therapy in this setting has not been formally evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262568\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapeutic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , 5-fluorouracil (5-FU),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    have been utilized in patients with locally advanced cutaneous SCC that cannot be adequately managed with surgical excision or radiation therapy or metastatic cutaneous SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/71\">",
"     71",
"    </a>",
"    ]. However, data on the efficacy of these interventions are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084865\">",
"    <span class=\"h2\">",
"     Management of nodal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive surgical resection of the nodal basins is the primary treatment modality for histologically confirmed lymph node involvement. The administration of ART following resection has improved locoregional disease control in patients with involvement of parotid and cervical nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/72\">",
"     72",
"    </a>",
"    ]. In a prospective study of 87 patients with high-risk cutaneous SCC metastatic to the parotid gland followed for a minimum of two years, a multivariate analysis demonstrated that failure to have postoperative radiation was an independent predictor of reduced disease control in the parotid region [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/73\">",
"     73",
"    </a>",
"    ]. In addition, a retrospective review of 167 immunocompetent patients with cutaneous SCC metastatic to the lymph nodes found a lower rate of recurrence in patients who received lymphadenectomy and ART compared to patients treated with lymphadenectomy alone (20 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262614\">",
"    <span class=\"h1\">",
"     ORGAN TRANSPLANT RECIPIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to cutaneous squamous cell carcinoma (cutaneous SCC) in organ transplant recipients is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link&amp;anchor=H2294558#H2294558\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956778\">",
"    <span class=\"h1\">",
"     ORAL RETINOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although oral retinoids may reduce the development of new primary cutaneous squamous cell carcinomas (cutaneous SCCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], a six-month randomized trial in which patients were given a combination of oral 13-cis-retinoic acid (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and interferon alfa (3 million units three times per week) or no adjuvant therapy failed to find a reduction in the risk for tumor recurrence in patients treated with this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/77\">",
"     77",
"    </a>",
"    ]. Based upon the lack of evidence to support the efficacy of oral retinoids for the prevention of tumor recurrence or metastasis in patients with high-risk cutaneous SCC, we cannot recommend the routine use of oral retinoids for this indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H31#H31\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Chemoprevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link&amp;anchor=H2294621#H2294621\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Chemoprevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90084886\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 to 80 percent of recurrences or metastases of cutaneous squamous cell carcinoma (cutaneous SCC) occur within two years after therapy, and approximately 95 percent occur within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, close follow-up is indicated.",
"   </p>",
"   <p>",
"    Specific guidelines for frequency and duration of follow-up for patients with a history of high-risk cutaneous SCC have not been established. We agree with the general guidelines proposed by the NCCN for patients with cutaneous SCC, which recommend performing a full skin exam and a regional lymph node exam according to the following schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patients with local disease:",
"      </strong>",
"      every three to six months for two years, then every six to twelve months for three years, then annually for life",
"     </li>",
"     <li>",
"      <strong>",
"       Patients with regional disease:",
"      </strong>",
"      every one to three months for one year, then every two to four months for one year, then every four to six months for three years, then every six to twelve months for life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At follow-up appointments, patients should be questioned about symptoms of pain, focal weakness, and numbness in the region of the tumor, and patients with head and neck tumors should receive a basic cranial nerve examination. The presence of neurologic symptoms may be indicative of tumor recurrence involving the nerves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients experience postsurgical sensory defects that may or may not slowly improve over time. Worsening signs or symptoms of neurologic dysfunction should raise concern for a recurrent tumor. &nbsp;",
"   </p>",
"   <p>",
"    The optimal frequency of follow-up may vary from the above based upon the clinician&rsquo;s assessment of the risk for recurrence; more frequent follow-up may be appropriate for some patients. Clinical findings suggestive of locoregional or distant metastasis should be evaluated with an appropriate modality. Some authors have recommended the routine use of ultrasonography for the detection of nonpalpable lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/46/21226/abstract/2\">",
"     2",
"    </a>",
"    ]; however, the value of routinely performing this procedure requires further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link&amp;anchor=H19785703#H19785703\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\", section on 'Squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956828\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous squamous cell carcinoma (cutaneous SCC) is a relatively common form of skin cancer that is curable in a high percentage of patients. A small proportion of patients develop aggressive disease characterized by local recurrence or regional or distant metastases. (See",
"      <a class=\"local\" href=\"#H858903\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple clinical and pathological features have been labeled as indicators of increased risk for aggressive tumor behavior. Tumor location, tumor size, tumor status as primary or recurrent, and associated symptoms should be assessed during the clinical evaluation. (See",
"      <a class=\"local\" href=\"#H90084731\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several pathologic features portend an increased likelihood for aggressive tumor behavior. Tumors that are not well-differentiated, tumors with desmoplastic growth patterns, thick tumors, and tumors with perineural invasion are considered high-risk lesions. (See",
"      <a class=\"local\" href=\"#H90084761\">",
"       'Histologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with high-risk cutaneous SCC begins with an assessment of the extent of disease based upon clinical, pathological, and radiologic features (",
"      <a class=\"graphic graphic_table graphicRef78140 \" href=\"UTD.htm?5/0/5134\">",
"       table 2B",
"      </a>",
"      ). The value of sentinel lymph node biopsy in high-risk cutaneous SCC is uncertain, but the procedure may be underutilized in high-risk SCC. (See",
"      <a class=\"local\" href=\"#H90084812\">",
"       'Staging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link\">",
"       \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical therapy is the primary treatment for patients with high-risk cutaneous SCC. For patients with surgically resectable tumors we recommend treatment with Mohs micrographic surgery or surgical excision with complete circumferential peripheral and deep margin assessment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H90084851\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for adjuvant radiation therapy following the attainment of clear surgical margins are unclear. In accordance with NCCN guidelines, we suggest the use of ART in patients with tumors that exhibit extensive perineural or large-nerve involvement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also consider ART for patients with cutaneous SCC with multiple risk factors, particularly those with highly infiltrative growth",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor differentiation in which surgical margins are uncertain. Radiation therapy may also be used as a primary therapy for patients who are not candidates for surgery. (See",
"      <a class=\"local\" href=\"#H90084858\">",
"       'Radiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with aggressive cutaneous SCC require frequent clinical follow-up to evaluate for signs of disease recurrence and the development of new cutaneous SCCs. The frequency of follow-up is dependent upon the extent of disease. A full skin examination, palpation of regional lymph nodes, and evaluation for neurologic symptoms should be performed at every follow-up visit. (See",
"      <a class=\"local\" href=\"#H90084886\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/1\">",
"      Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/2\">",
"      Brantsch KD, Meisner C, Sch&ouml;nfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/3\">",
"      Samarasinghe V, Madan V, Lear JT. Management of high-risk squamous cell carcinoma of the skin. Expert Rev Anticancer Ther 2011; 11:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/4\">",
"      Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 2011; 64:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/5\">",
"      Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/6\">",
"      Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012; 106:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/7\">",
"      Jambusaria-Pahlajani A, Hess SD, Katz KA, et al. Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons. Arch Dermatol 2010; 146:1225.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/9\">",
"      Jambusaria-pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/10\">",
"      Schmults CD, Karia PS, Carter JB et al. (in press). Factors predictive of recurrence and death from cutaneous squamous cell carcinoma. JAMA Dermatol.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/11\">",
"      Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg 2006; 32:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/12\">",
"      Mullen JT, Feng L, Xing Y, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol 2006; 13:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/13\">",
"      Kraus DH, Carew JF, Harrison LB. Regional lymph node metastasis from cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1998; 124:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/14\">",
"      Ross AS, Whalen FM, Elenitsas R, et al. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study. Dermatol Surg 2009; 35:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/15\">",
"      Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg 2002; 28:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/16\">",
"      Breuninger H, Black B, Rassner G. Microstaging of squamous cell carcinomas. Am J Clin Pathol 1990; 94:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/17\">",
"      Veness MJ, Palme CE, Morgan GJ. High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease. Cancer 2006; 106:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/18\">",
"      Tavin E, Persky M. Metastatic cutaneous squamous cell carcinoma of the head and neck region. Laryngoscope 1996; 106:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/19\">",
"      Veness MJ, Porceddu S, Palme CE, Morgan GJ. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 2007; 29:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/20\">",
"      Edwards MJ, Hirsch RM, Broadwater JR, et al. Squamous cell carcinoma arising in previously burned or irradiated skin. Arch Surg 1989; 124:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/21\">",
"      Mendenhall WM, Ferlito A, Takes RP, et al. Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol 2012; 48:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/22\">",
"      Mendenhall WM, Amdur RJ, Hinerman RW, et al. Skin cancer of the head and neck with perineural invasion. Am J Clin Oncol 2007; 30:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/23\">",
"      Balamucki CJ, Mancuso AA, Amdur RJ, et al. Skin carcinoma of the head and neck with perineural invasion. Am J Otolaryngol 2012; 33:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/24\">",
"      Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP. Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer 1997; 79:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/25\">",
"      Salmon PJ, Hussain W, Geisse JK, et al. Sclerosing squamous cell carcinoma of the skin, an underemphasized locally aggressive variant: a 20-year experience. Dermatol Surg 2011; 37:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/26\">",
"      Garcia C, Crowson AN. Acantholytic squamous cell carcinoma: is it really a more-aggressive tumor? Dermatol Surg 2011; 37:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/27\">",
"      Yang A, Hanley A, Velazquez EF, Cassarino DS. Primary cutaneous myxoid spindle cell squamous cell carcinoma: a clinicopathologic study and review of the literature. J Cutan Pathol 2010; 37:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/28\">",
"      Goepfert H, Dichtel WJ, Medina JE, et al. Perineural invasion in squamous cell skin carcinoma of the head and neck. Am J Surg 1984; 148:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/29\">",
"      Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol 2005; 23:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/30\">",
"      Carter JB, Johnson MM, Chua TL, et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol 2013; 149:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/31\">",
"      Lin C, Tripcony L, Keller J, et al. Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. Int J Radiat Oncol Biol Phys 2012; 82:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/32\">",
"      Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/33\">",
"      Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/34\">",
"      Jensen P, Hansen S, M&oslash;ller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/35\">",
"      Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/36\">",
"      Smith KJ, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. Dermatol Surg 2004; 30:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/37\">",
"      Frierson HF Jr, Deutsch BD, Levine PA. Clinicopathologic features of cutaneous squamous cell carcinomas of the head and neck in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol 1988; 19:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/38\">",
"      Mehrany K, Weenig RH, Lee KK, et al. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol 2005; 53:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/39\">",
"      Mehrany K, Weenig RH, Pittelkow MR, et al. High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia. Dermatol Surg 2005; 31:38.",
"     </a>",
"    </li>",
"    <li>",
"     Fine JD, Bauer EA, McGuire J, et al. Epidermolysis bullosa. In: Clinical, Epidemiologic and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry, The Johns Hopkins University Press, Baltimore, MD 2000. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/41\">",
"      Pourreyron C, Cox G, Mao X, et al. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression. J Invest Dermatol 2007; 127:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/42\">",
"      Sulica VI, Kao GF. Squamous-cell carcinoma of the scalp arising in lesions of discoid lupus erythematosus. Am J Dermatopathol 1988; 10:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/43\">",
"      Mulwafu WK, Fagan JJ, Jessop S. Squamous cell carcinoma in black patients with discoid lupus erythematosus. S Afr J Surg 2006; 44:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/44\">",
"      Gr&eacute;co M, Kupfer-Bessaguet L, Delahaye JF, Plantin P. Multiple cutaneous squamous cell carcinomas arising in a patient with generalized morphea. Eur J Dermatol 2006; 16:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/45\">",
"      Gmeinhart B, Hinterberger W, Greinix HT, et al. Anaplastic squamous cell carcinoma (SCC) in a patient with chronic cutaneous graft-versus-host disease (GVHD). Bone Marrow Transplant 1999; 23:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/46\">",
"      Constantinou C, Widom K, Desantis J, Obmann M. Hidradenitis suppurativa complicated by squamous cell carcinoma. Am Surg 2008; 74:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/47\">",
"      Glazer ES, Bartels PH, Prasad AR, et al. Nuclear morphometry identifies a distinct aggressive cellular phenotype in cutaneous squamous cell carcinoma. Cancer Prev Res (Phila) 2011; 4:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/48\">",
"      Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/49\">",
"      Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/50\">",
"      Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/51\">",
"      Ch'ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 2008; 39:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/52\">",
"      Giacchero D, Barri&egrave;re J, Benezery K, et al. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma--a report of eight cases. Clin Oncol (R Coll Radiol) 2011; 23:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/53\">",
"      Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29:3419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/54\">",
"      Sweeny L, Dean NR, Magnuson JS, et al. EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck 2012; 34:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/55\">",
"      Clark JR, Rumcheva P, Veness MJ. Analysis and comparison of the 7th edition American Joint Committee on Cancer (AJCC) nodal staging system for metastatic cutaneous squamous cell carcinoma of the head and neck. Ann Surg Oncol 2012; 19:4252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/56\">",
"      Breuninger H, Brantsch K, Eigentler T, H&auml;fner HM. Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges 2012; 10:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/57\">",
"      Kwon S, Dong ZM, Wu PC. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature. World J Surg Oncol 2011; 9:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/58\">",
"      Pugliano-Mauro M, Goldman G. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 2010; 36:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/59\">",
"      Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/60\">",
"      Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion. J Am Acad Dermatol 2005; 53:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/61\">",
"      Ad Hoc Task Force, Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 2012; 67:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/62\">",
"      Panizza B, Solares CA, Redmond M, et al. Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck. Head Neck 2012; 34:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/63\">",
"      Solares CA, Lee K, Parmar P, et al. Epidemiology of clinical perineural invasion in cutaneous squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 2012; 146:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/64\">",
"      LeBoeuf NR, Schmults CD. Update on the management of high-risk squamous cell carcinoma. Semin Cutan Med Surg 2011; 30:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/65\">",
"      Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/66\">",
"      Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw 2010; 8:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/67\">",
"      Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004; 60:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/68\">",
"      Jambusaria-Pahlajani A, Miller CJ, Quon H, et al. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009; 35:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/69\">",
"      Waxweiler W, Sigmon JR, Sheehan DJ. Adjunctive radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion. J Surg Oncol 2011; 104:104.",
"     </a>",
"    </li>",
"    <li>",
"     Cox J. Radiation Oncology: Rationale, Techniques, Results, 8th ed, Mosby, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/71\">",
"      Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010; 15:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/72\">",
"      Bumpous J. Metastatic cutaneous squamous cell carcinoma to the parotid and cervical lymph nodes: treatment and outcomes. Curr Opin Otolaryngol Head Neck Surg 2009; 17:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/73\">",
"      O'Brien CJ, McNeil EB, McMahon JD, et al. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002; 24:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/74\">",
"      Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005; 115:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/75\">",
"      Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006; 54:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/76\">",
"      Toma S, Bonelli L, Sartoris A, et al. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 2004; 11:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/46/21226/abstract/77\">",
"      Brewster AM, Lee JJ, Clayman GL, et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 2007; 25:1974.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13713 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21226=[""].join("\n");
var outline_f20_46_21226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H956828\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90084715\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H858903\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90084722\">",
"      HIGH-RISK FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084731\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90084740\">",
"      - Anatomic location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90084747\">",
"      - Tumor diameter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90084754\">",
"      - Recurrent tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33739498\">",
"      - Location in sites of chronic wounds, scars, or ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17872898\">",
"      - Neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084761\">",
"      Histologic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4455948\">",
"      - Histologic grade and subtype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90084768\">",
"      - Tumor thickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90084775\">",
"      - Perineural invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084805\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4456126\">",
"      Other features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4456021\">",
"      - Nuclear morphometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4456036\">",
"      - Epidermal growth factor receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90084812\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084821\">",
"      Staging systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084828\">",
"      Tools for staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084835\">",
"      Sentinel lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90084842\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084851\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1262413\">",
"      - Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1262420\">",
"      - Excision with complete margin assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1262427\">",
"      - Conventional surgical excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H480333\">",
"      - Extensive cases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084858\">",
"      Radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1262568\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90084865\">",
"      Management of nodal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1262614\">",
"      ORGAN TRANSPLANT RECIPIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H956778\">",
"      ORAL RETINOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90084886\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H956828\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13713\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13713|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/50/1837\" title=\"table 1\">",
"      Cutaneous squamous cell carcinoma recurrence and metastasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/43/22203\" title=\"table 2A\">",
"      NCCN risk factors for cutaneous SCC recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/0/5134\" title=\"table 2B\">",
"      TNM stage cutaneous SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/54/13163\" title=\"table 3\">",
"      Side effects of radiation therapy for cutaneous SCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37832?source=related_link\">",
"      Epidemiology and risk factors for skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=related_link\">",
"      Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=related_link\">",
"      Management of skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=related_link\">",
"      Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_46_21227="Ancillary testing in MS";
var content_f20_46_21227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ancillary testing in multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent abnormal in patients with definite multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual evoked response (VER)",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brainstem auditory evoked response (BAER)",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatosensory evoked potentials (SEP)",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrospinal fluid oligoclonal banding",
"       </td>",
"       <td>",
"        85 to 95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG index of spinal fluid",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrospinal fluid albumin",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain MRI",
"       </td>",
"       <td>",
"        70 to 95",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Nuwer, MR, Packwood, JW, Myers, LW, Ellison, GW, Neurology 1987; 37:1754 and McLean, BN, Luxton, RW, Thompson, EJ, Brain 1990; 113:1269 and Rudick, RA, Whitaker, JN, in Scheinberg, P (Ed), Neurology/neurosurgery update series, Princeton, NJ, 1987 and Paty, DW, Oger, JJ, Kastrukoff, LF, et al, Neurology 1988; 38:180.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21227=[""].join("\n");
var outline_f20_46_21227=null;
var title_f20_46_21228="Oral antibiotics for suspected cholera";
var content_f20_46_21228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral antibiotics for suspected cholera",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibiotic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical pediatric dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Tetracyclines",
"        </strong>",
"       </td>",
"       <td>",
"        Doxycycline",
"       </td>",
"       <td>",
"        4-6 mg/kg (single dose)",
"       </td>",
"       <td>",
"        300 mg (single dose)",
"       </td>",
"       <td rowspan=\"2\">",
"        Antibiotic resistance to all tetracyclines is common",
"        <sup>",
"         [1]",
"        </sup>",
"        . Empiric use is appropriate in epidemics caused by documented susceptible isolates. Not recommended for pregnant women and children less than 8 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetracycline",
"       </td>",
"       <td>",
"        50 mg/kg/day in four equally divided doses, for three days",
"       </td>",
"       <td>",
"        500 mg four times per day for three days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Macrolides",
"        </strong>",
"       </td>",
"       <td>",
"        Azithromycin",
"       </td>",
"       <td>",
"        20 mg/kg (single dose)",
"       </td>",
"       <td>",
"        1 g (single dose)",
"       </td>",
"       <td rowspan=\"2\">",
"        Single dose azithromycin is preferred therapy",
"        <sup>",
"         [2]",
"        </sup>",
"        . Rare reports of macrolide resistance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"       <td>",
"        40 mg/kg/day in four equally divided doses, for three days",
"       </td>",
"       <td>",
"        500 mg four times per day for three days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Fluoroquinolones",
"        </strong>",
"       </td>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        20 mg/kg (single dose)",
"       </td>",
"       <td>",
"        1 g (single dose)",
"       </td>",
"       <td>",
"        Reduced susceptibility to fluoroquinolones has been reported in Asia and Africa",
"        <sup>",
"         [2,3]",
"        </sup>",
"        . Not recommended for pregnant women and children less than 8 years.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Not to exceed maximum dose.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Yamamoto T, Nair GB, Albert MJ, et al. Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents. Antimicrob Agents Chemother 1995; 39:241.",
"       </li>",
"       <li>",
"        Saha D, Karim MM, Khan WA, et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006; 354:2452.",
"       </li>",
"       <li>",
"        Islam MS, Midzi SM, Charimari L, et al. Susceptibility to fluoroquinolones of Vibrio cholerae O1 isolated from diarrheal patients in Zimbabwe. JAMA 2009; 302:2321.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21228=[""].join("\n");
var outline_f20_46_21228=null;
var title_f20_46_21229="Survival advantage of arterial coronary bypass grafts";
var content_f20_46_21229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival advantage of arterial coronary bypass grafts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated survival rates for patients with angina who underwent internal mammary artery (IMA, n = 749) or saphenous vein (n = 4888) coronary bypass grafts. Patient survival was significantly prolonged with IMA grafts (64 versus 53 percent at 15 years), a difference that increased over time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cameron A, Davis KB, Green G, Schaff HV. N Engl J Med 1996; 334:216.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21229=[""].join("\n");
var outline_f20_46_21229=null;
var title_f20_46_21230="Ischemic optic disc in GCA";
var content_f20_46_21230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ischemic optic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ischemic optic neuropathy in a patient with giant cell artertitis who lost vision abruptly four days prior to this examination. The optic disc is swollen and its margins are blurred.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gene Hunder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21230=[""].join("\n");
var outline_f20_46_21230=null;
var title_f20_46_21231="ACE inhibitor in LV dysfunction";
var content_f20_46_21231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75136%7ECARD%2F70015%7ECARD%2F62325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75136%7ECARD%2F70015%7ECARD%2F62325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enalapril improves outcome in asymptomatic LV dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the SOLVD prevention trial of 4228 patients (83 percent post-MI) with asymptomatic left ventricular dysfunction, prophylactic administration of enalapril reduced the probability of death or heart failure (p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The SOLVD Investigators. N Engl J Med 1992; 327:685.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor improves survival in moderate HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enalapril, compared to placebo, decreases patient mortality in NYHA class II and III heart failure (p = 0.0036).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The SOLVD Investigators, N Engl J Med 1991; 325:293.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor improves survival in advanced HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 242px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Decreased mortality in patients with advanced NYHA class III or IV heart failure after treatment with enalapril compared to placebo (p = 0.003).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The CONSENSUS Trial Study Group, N Engl J Med 1987; 316:1429.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_46_21231=[""].join("\n");
var outline_f20_46_21231=null;
